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Co-chairs: Renny T. Franceschi and Kurt D. Hankenson 
Mesenchymal Stem Cells (MSC) give rise to osteoblasts, adipocytes and 
chondrocytes.  A decrease in MSC number and a shift in their differentiation to 
the adipogenic fate is observed with aging and have been proposed as possible 
mechanisms for the pathogenesis of age associated osteoporosis.  Mice deficient 
in thrombospondin-2 (TSP2) have an increase in MSC number and as a result, 
TSP2-null mice have an increase in bone mass.   In-vitro, TSP2 promotes 
osteogenic differentiation and inhibits MSC proliferation.  There is a reciprocal 
relationship between osteogenic and adipogenic differentiation such that factors 
which promote osteogenic differentiation inhibit adipogenic differentiation, 
therefore we hypothesized that TSP2 inhibits adipogenesis.  MSC isolated from 
bone marrow as well as adipose tissue of TSP2-null mice display an increase in 
lipid accumulation relative to those isolated from wild type mice.   In addition 
TSP2-null mice are heavier due to increased adiposity.  
 
 x 
Recent studies have demonstrated that TSP2 modulates activation of 
notch signaling in various cell types.  Activation of Notch signaling by plating 
MSC onto Jagged-1 increases primary MSC proliferation, and decreases 
osteogenic differentiation.  Jagged-1 also increases lipid accumulation in part by 
increasing their proliferation.  Expressing a dominant negative form of 
mastermind-like-1 (dnMAML) to selectively inactivate canonical notch signaling in 
vivo in osteoblasts results in vertebral malformations similar to Alagille Syndrome 
patients.  dnMAML expression in early mesenchymal tissue results in decreased 
trabecular bone volume fraction at 8 weeks of age but has no apparent effect on 
trabecular bone at 6 or 14.5 months of age. Post-natal induction of global 
dnMAML expression results in decreased trabecular bone at 6 months of age 
without significantly altering CFU-F numbers suggesting the decrease in bone 
mass could be secondary to increased bone resorption.   
We evaluated the effect of TSP2 on Jagged-1 mediated notch activation 
and found that notch target gene expression is increased in TSP2-null MSC.  
Over-expressing TSP2 in C3H10T1/2 cells decreases Hey-1 expression and 
notch reporter activity.  We propose a model in which TSP2 decreases notch 
activation resulting in a decrease in MSC proliferation and an increase in 








Bone is a dynamic organ that is remodeled throughout life.  Bone 
remodeling, the process of removing old bone (bone resorption) and replacing it 
with new (bone formation), is maintained in homeostasis (1, 2).  Conditions that 
disrupt this equilibrium and cause a net increase in bone resorption lead to 
decreased bone mass (osteopenia).   If osteopenia is severe enough, it leads to 
the clinical condition osteoporosis which is characterized by increased risk of 
bone fracture (3).    
In the U.S., more than 10 million individuals have clinical osteoporosis and 
greater than 34 million more have low bone mass. Osteoporosis is responsible 
for more than 1.5 million fractures annually. It is estimated that one out of every 
two women and one in eight men over age 50 will have an osteoporosis-related 
fracture in their lifetime.  The number of patients with osteoporosis is likely to 
increase in the future due to changes in demographics and increases in life 
expectancy (4, 5). 
Although the causes of osteoporosis are multi-factorial and likely involve 
many risk factors, the most common causes of osteoporosis are associated with 
aging and are classified as type I (estrogen associated) and type II (senile 
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or age associated).  In type I osteoporosis, the loss of estrogen leads to an 
increase in bone resorption, and although there is a concomitant increase in 
bone formation, it is unable to balance the increased bone resorption.  In type II 
osteoporosis, both bone formation and bone resorption decrease with age but 
the decrease in bone formation is greater than the decrease in bone resorption 
(6-11).   
Bone remodeling is accomplished by osteoclasts which resorb bone and 
osteoblasts which lay down new bone.  Osteoclasts are derived from 
hematopoetic stem cells (HSC) while osteoblasts are derived from mesenchymal 
stem cells (MSC).  Although most clinically available treatments for osteoporosis 
target bone resorption, a significant limitation of this approach is that it is 
ineffective at increasing bone mass in patients who are already osteopenic.  
Novel treatment approaches will target osteoblasts and aim at increasing their 
number by driving their differentiation from MSC or increasing their proliferation, 
survival or activity.   
 
Mesenchymal Stem Cells (MSC) -“Osteogenic Stem Cells”  
Seminal work by Friedenstein and colleagues in the 1960’s and 70’s 
showed that when whole bone marrow is plated onto tissue culture plastic, 
fibroblastic, adherent colonies are formed which they termed colony-forming-unit-
fibroblastic (CFU-F).  Using in vitro and in vivo implantation experiments, they 
showed that all of the “osteogenic activity” resided in these adherent cells and 
proposed the existence of an “osteogenic stem cell”, distinct from HSC, that 
 
 3 
gives rise to the osteoblast lineage (12-15).  Subsequent experiments showed 
that plating whole bone marrow at very low density gives rise to single cell 
derived CFU-F that had significant proliferative capacity and the ability to 
differentiate into osteoblasts, adipocytes and chondrocytes (16).  Cells derived 
from these clones were also able to form bone when implanted into host animals 
which firmly established the existence of cells with stem cell like properties (17).  
With later demonstration that this adherent population of bone marrow cells can 
be induced to differentiate into other mesenchymal derived tissues such as 
muscle, the term ‘Mesenchymal Stem Cell’ was proposed and has gained wide 
use to describe not only those fibroblastic cells derived from bone marrow but 
also similar cells derived from other connective tissues that show similar 
differentiation potential (18, 19).    
 
MSC differentiation potential 
 In their native endocortical bone environment, MSC give rise to 
osteoblasts, adipocytes, and stromal support cells.   During embryonic 
development and bone regeneration processes such as during fracture healing, 
MSC also differentiate into chondrocytes.  Various studies show that bulk 
cultures of marrow stromal cells can also be induced to differentiate into various 
cell types including neurons, muscle cells and tendon-like tissue (20-22).  
However, single cell derived MSC have been demonstrated to only differentiate 
into osteoblasts, adipocytes and chondrocytes.  Additionally, the ability of MSC to 
differentiate into other lineages has not been demonstrated in vivo, therefore, 
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whether MSC give rise to any other committed, fully-differentiated lineages 
remains controversial (19).   
 In vivo, bone formation involves commitment of MSC into pre-osteoblasts.  
As pre-osteoblasts mature into active osteoblasts, they change in morphology to 
polarized, cuboidal cells that line the bone surface and secrete osteoid, an un-
mineralized bone matrix that is rich in type I collagen, and other non-structural 
extracellular matrix proteins (ECM) proteins.  Some osteoblasts surround 
themselves with bone matrix and these cells are referred to as osteocytes 
present in lacunae (23).    
Several key transcription factors involved in osteoblastogenesis have 
been identified through a combination of genetic and molecular studies.  Runx-2, 
a runt homology domain transcription factor, was initially identified in a screen of 
proteins that bind to the promoter of the osteoblast specific osteocalcin gene (24, 
25).   In humans, haploinsufficiency in Runx-2 causes an autosomal dominant 
disease called cleidocranial dysplasia (CCD) that is characterized by partial or 
complete absence of the clavicles, unclosed fontanelles, short stature, 
underdeveloped bones, and supernumerary teeth (26, 27).   Transgenic mice in 
which both copies of Runx-2 have been disrupted by homologous targeting 
(Runx-2-/-) develop no osteoblasts while Runx-2+/- mice display a phenotype 
similar to CCD (28, 29).   In vitro, forced expression of Runx-2 in non-osteogenic 
cells results in expression of many osteoblast specific ECM proteins  establishing 
Runx-2 as “master regulator” of osteogenesis (30).   
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Another transcription factors required for osteogenesis is the zinc finger 
containing protein osterix (Sp7).  Osterix null mice completely lack osteoblasts.  
The fact that Runx-2 null mice do not express osterix while Runx-2 expression is 
normal in osterix null mice, along with in vitro experiments showing that Runx-2 
over-expression induces osterix suggests that osterix is a down stream target of 
Runx-2 (31) .  A recent study that examined the phenotype of mice in which 
osterix expression was specifically deleted in osteoblasts using 2.3kb type I 
collagen promoter, demonstrated an osteopenic phenotype accompanied by an 
increase in immature osteoblasts indicating that osterix plays an important role in 
terminal differentiation of osteoblasts (32).  
Another transcription factor that regulates osteogenic differentiation is 
ATF4.  Mice deficient in ATF4 are osteopenic due to defect in terminal 
differentiation of osteoblasts and defect in type I collagen synthesis (33).  ATF4 
regulates osteocalcin gene transcription and its transcriptional activity is in turn 
regulated by FIAT (33-39).  Over-expression and deletion studies have also 
identified other transcription factors including ΔFosB, Fra-1, Dlx5 and Dlx6 that 
play a role in regulating osteoblast differentiation (40-50)  
 
Adipogenic differentiation 
 Adipogenic differentiation, including its transcriptional regulation, has been 
extensively characterized in pre-adipocyte cell lines such as 3T3-L1 cells.  Upon 
adipogenic induction, pre-adipocytes undergo 2-3 cycles of cell division in a 
process referred to as mitotic clonal expansion,  and begin to express high levels 
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of transcription factors of the C/EBP family which in turn activate PPAR-γ 
expression.  PPAR-γ is a member of the nuclear receptor family of transcription 
factors and is referred to as master-regulator of adipogenesis because its 
expression is both necessary and sufficient for adipogenesis.  PPAR-γ activates 
transcription of many genes that are required for adipocyte function (51-53). As 
cells differentiate and mature into adipocytes, they undergo changes in their 
morphology from fibroblastic (spindle-shape and stellate) to rounded and they 
eventually accumulate lipid droplets.   Although there is some argument as to 
whether primary MSC undergo mitotic clonal expansion, they clearly exhibit 
similar changes in expression of key adipocyte specific transcription factors, 
undergo similar morphological changes and accumulate lipid droplets (54). 
 
Reciprocal relationship between osteogenesis and adipogenesis 
  An increase in bone marrow adipocytes is observed in several bone loss 
conditions including those caused by aging (11, 55-57).   There is also an inverse 
correlation between increased adipocyte number and reduced bone formation 
rate in humans (58).  Additionally, many growth factors such as Wnts which 
promote osteogenesis, also decrease adipogenesis (59-61).  
In vitro and in vivo studies demonstrate interactions between transcription 
factors that regulate differentiation into the two fates.  In animal models, 
decreasing PPAR-γ activity results in increased osteoblast differentiation and 
bone mass.  Similarly, a decrease in bone mass is observed when PPAR-γ 
agonists are administered to either mice or humans (62-65).  A study by Hong et 
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identified TAZ (transcriptional co-activator with PDZ-binding motif) as a BMP2 
induced protein that acts as a transcriptional co-activator for Runx-2 and 
promotes osteogenic differentiation of MSC.  Interestingly, TAZ also acts as a co-
repressor for PPAR-γ mediated transcription and acts to inhibit adipogenesis 
suggesting that it may play an important role in a switch from an adipogenic to 
osteogenic fate (66). 
 
Systemic and local control of MSC differentiation and bone formation 
 Several systemic hormones have been shown to regulate bone mass. 
Parathyroid hormone (PTH) has both anabolic and catabolic effects on bone.  
Intermittent PTH administration results in increased osteoblast number and bone 
formation and is used clinically for the treatment of osteoporosis, while chronic 
administration results in an increase in osteoclast number and bone resorption 
(67).  PTH has been shown to affect osteoblast proliferation and survival in vitro 
and in vivo (68, 69).  In addition, PTH has a positive effect on osteoclast function 
by inducing osteoblasts to produce RANKL and M-CSF, two factors that promote 
osteoclast function. 
Adipocyte produced leptin is another hormone that has been shown to 
have complex effects on bone.  Leptin deficient (ob/ob) mice have a decrease in 
most bone parameters including total body bone mineral density, long bone 
cortical thickness and mineralizing surface but have an increase in trabecular 
bone.  A similar bone phenotype is observed in leptin receptor deficient (db/db) 
mice.  Leptin appears to exert its negative effect on bone though its effect on 
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catecholamine release from the central nervous system.  Other systemic 
hormones that regulate bone mass include steroid hormones estrogen and 
progesterone, vitamin-D3, and glucocorticoids (70-73). 
 Several, locally produced growth factors, including  BMPs and Wnts also 
play crucial roles in regulating MSC differentiation and bone formation.   BMPs 
are members of the TGF-β super family and play important roles in skeletal 
development.   MSC and osteoblasts secrete several BMPs including BMP-2, -4,-
6 and -7 which have been shown to promote bone formation in various cell types 
(74).  Additionally, activation of BMP signaling in vivo has been shown to cause 
heterotopic ossification (75-77).   BMPs signal through receptor tyrosine kinases.  
Receptor binding results in phosphorylation of the receptor activated smads (R-
Smads).  R-Smads then bind to common mediator smad (Smad 4), translocate to 
the nucleus and initiate transcription of target genes (78).    
 Wnts are another group of growth factors produced by MSC lineage cells. 
Although it is now clear that Wnts can signal through different mechanisms, the 
best characterized signaling process, the canonical pathway, acts through the 
stabilization of β-catenin.  In the absence of Wnt, β-catenin is phosphorylated by 
GSK-3β and is directed for proteosomal degradation.  Binding of Wnts to frizzed 
receptors and LRP5 and LRP6 initiates a signaling cascade that blocks GSK-3β 
activity and causes β-catenin to accumulate in the cytoplasm.  β-catenin then 
translocates to the nucleus, binds to TCF/LEF family of transcription factors and 
initiates transcription of Wnt target genes.  In humans, loss off function mutations 
in LRP5 result in decreased bone mass while gain of function mutations result in 
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increased bone mass.  Transgenic mice with similar gain of function mutation in 
LRP5 show increase in bone mass while LRP5 and LRP6 null mice show defect 
in bone mass accrual (79).  Transgenic mice that over-express Wnt-10b 
specifically in adipocytes from AP2 promoter  have an increase in bone mass 
and a decrease in fat tissue (60).  In-vitro, Wnt10b promotes osteogenic 
differentiation and blocks adipogenic differentiation by inhibiting expression of 
CEBP and PPAR-γ expression (80).  
 MSC differentiation is also influenced by extracellular matrix (ECM) 
proteins.  Cells interact with the ECM thorough a variety of receptors including 
integrins.  Integrin binding to the ECM activates signaling through the MAP 
kinase pathway which in turn has been shown to post-translationally modify 
Runx-2 and increase it transcriptional activity (81-83).    Cell adhesion and shape 
also have been shown to influence cell differentiation.  For instance, heparin 
promotes adipogenic differentiation and inhibits osteogenic differentiation by 
decreasing focal adhesion formation (84).  Plating MSC on substrates that allow 
cell spreading promotes their differentiation into the osteogenic lineage while 
substrates that cause them to have a rounded shape promote adipogenic 
differentiation (85).   
 MSC secrete a variety of ECM proteins.  While some of these ECM 
proteins are vital for the structural integrity of bone, others referred to as 
matricellular proteins, play a minimal structural role but rather are important in 
mediating interactions between cells and the extracellur environment (86-88). 
Several mouse knock out models have revealed that matricellular proteins play 
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important roles in MSC physiology.   As examples, osteonectin-null mice develop 
age-associated osteopenia due to a decrease in MSC number, while the 
phenotype of osteopontin-null mice is more subtle and best revealed through 
physiological challenges such as ovariectomy and fracture (88). 
 
Thrombospondin-2 
 Thromospondin-2 (TSP2) is a matricellular protein that is highly expressed 
in MSC.  It belongs to a family of five structurally related proteins (TSP1-TSP5).  
TSP1 was the first member to be identified as a factor secreted from thrombin-
stimulated platelets hence the name for the group.  TSPs are large, multi-
modular, glycoproteins that form either homotrimers (TSP1 and TSP2) or 
homopentamers (TSP3-TSP5).   In addition to being trimeric, TSP1 and TSP2 
have the same modular structure with an N-terminal heparin binding domain, a 
linker region, a procollagen-homology domain, three type I repeats, three EGF-
like type II repeats, seven calcium binding type III repeats and a globular C-
terminal domain.  TSP3-5 are structurally different from TSP1 and TSP2 and 
form pentamers, lack procollagen and type I repeats, and have four instead of 
three type II repeats (89-91). 
 TSP2 expression in vivo has been evaluated most extensively in mouse 
embryos.  TSP2, as measured by in-situ hybridization and immuno-
histochemistry, is highest in organs with high connective tissue content such as 
dermis, blood vessels, meninges, ligaments, pericardium, periosteum, and pleura.  
TSP2 expression is also high in the developing skeleton and muscle.  In the 
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developing skeleton, TSP2 expression localizes to the proliferative zone of 
growth plates and to bony spicules in the endosteal space (92-94).   TSP2 
expression is highest in undifferentiated mesenchymal cells five days post 
fracture in a tibial fracture model and its expression decreases in more mature 
fracture calluses (95).   
 Analysis of the phenotype of TSP2-null mice has revealed that TSP2 has 
important function in several tissues.  TSP2 null mice have tendon and ligament 
laxity due to abnormal collage fibrillogenesis.  The skin of TSP2-null mice is 
fragile, which may be due to decreased adhesion and spreading of dermal 
fibroblasts.  Similar to TSP1, TSP2 also has anti-angiogenic properties as 
demonstrated by the increase vascular density in multiple tissues in TSP2-null 
mice (96-101).   
TSP2-null mice have also revealed an important role for TSP2 in bone 
homeostasis.  TSP2-null mice have an increase in cortical bone thickness due to 
an increase in endocortical bone formation.  Increases in bone formation can be 
accomplished either by increasing the number of osteoblasts or increasing the 
activity of osteoblasts that are present (102).  In vitro, MSC from TSP2 null mice 
display a delay in mineralization suggesting that TSP2 actually promotes 
osteogenic differentiation.  TSP2 also inhibits MSC proliferation in vitro and CFU-
F numbers are increased in TSP2 null mice suggesting the increase in bone 
formation observed in TSP2-null mice may be due to increased osteoblast 
progenitor number (102, 103). 
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The ability of TSP2 to influence such diverse cellular processes is due to its’ 
modular structure which allows it to interact with various cell surface receptors, 
secreted growth factors and cytokines, enzymes and other ECM proteins.  The 
N-terminal domain (NTD) of TSP1 and TSP2 contains high affinity heparin 
binding domains that bind to heparin-sulfate-proteoglycans.  The NTD is also 
responsible for interaction with the scavenger receptor, low density lipoprotein- 
related receptor protein (LRP) which is responsible for endocytosis and 
degradation of TSPs.  In addition, the NTD contains a binding domain for α3β1 
integrin.  TSP1 and TSP2 can bind to latent TGF-β through their type-I repeats.  
The type I repeats also interact with CD36 and this interaction has been shown to 
be important for the anti-angiogenic effects of TSP1.  In addition to binding 
calcium, the type III repeats contain an RGD domain that mediates interaction 
with αvβ3 and αIIbβ3 integrins.  Finally, the C-terminal domain interacts with 
another adhesion receptor, CD47/Integrin associated protein (IAP).   TSP2 also 
binds to matrix-metalloproteinase 2 (MMP2) and decreases it activity indirectly by 
promoting clearance by LRP mediated endocytosis (99, 104).  Most recently 
TSP2 was shown to physically interact with Notch receptors and ligands and 
regulate activation of this developmentally important signaling pathway (105). 
 
Notch Signaling 
 Notch receptors are evolutionarily conserved single pass transmembrane 
proteins. In mammals there are 4 known notch receptors (Notch1-4).    
Structurally, the extracellular domain of notch receptors is composed of a DSL 
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domain and from 28 to 36 EGF like repeats that are responsible for interaction 
with ligands, three LN repeats, and a heterodimerization domain.   The 
intracellular domain contains seven ankyrin repeats flanked by two nuclear 
localization signals (NLS), a transactivating domain, and a proline, glutamine, 
serine, threonine rich (PEST) domain.  The receptor is initially synthesized as a 
single precursor protein containing both the extracellular and intracellular 
domains but is cleaved during transport (S1 cleavage) in the trans-golgi by a 
furin-like convertase.  Following cleavage, the hydrophobic heterodimerization 
domain forms a stable, non-covalent complex with the extracellular portion of the 
membrane bound intracellular notch (106). 
The ligands for Notch receptors are also single pass transmembrane 
proteins expressed by neighboring cells.  In mammals there are five ligands 
(delta-like (Dll) 1, 3 and 4 and Jagged (Jag) 1 and 2).  Dll and Jag ligands are 
structurally similar in that they contain an N-terminus DSL domain and EGF like 
repeats responsible for receptor interaction. However Jag-1 and Jag-2 contain 
more EGF repeats than Dll1, 3 and 4 and also contain a cystine rich domain (107, 
108).   
 Ligand binding to notch receptors results in a series of enzymatic 
cleavages that ultimately results in release of the intracellular domain (NICD) into 
the cytoplasm.  The first of these cleavages, the S2 cleavage, is accomplished by 
the ADAM/TACE (a disintegrin and metallopeptidase/ tumor necrosis factor α 
converting enzyme) family of membrane bound proteases and results in 
shedding of the receptor’s ectodomain.  The remaining, membrane bound notch 
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receptor then undergoes two transmembrane cleavages (S3/S4) mediated by a 
γ-secretase enzyme complex composed of presenilins 1 and 2 (PSN), nicastrin 
(NCT), anterior pharynx defective-1 (Aph-1) and presenilin enhancer-2 (Pen-2).  
This cleavage releases NICD into the cytoplasm which then translocates into the 
nucleus and initiates transcription of notch target genes by interacting with the 
DNA binding CSL (for C-promoter binding factor1 (CBF-1), RBP-Jκ/Su(H) in 
mammals/Drosophila/ C.elegans)  protein.  In the absence of NICD, CSL 
normally binds to promoters of target genes in association with co-repressors 
including silencing mediator of retinoid and thyroid receptor (SMRT)/nuclear 
receptor co-receptor (N-coR) and SHARP (SMRT/HDAC-1 associated proteins).  
NICD interaction with CSL is mediated through its ankryrin repeats and results in 
displacement of co-repressors from CSL. NICD then recruits the transcriptional 
co-activator mastermind-like-1 (MAML).  Formation of this ternary complex 
between NICD, CSL and MAML, is required for recruitment of basic transcription 
machinery to initiate transcription of notch target genes (106-112).   
 The best characterized primary notch target genes are the beta helix-loop-
helix transcription factors of the HES/HERP family.  In mammals seven HES 
(HES1-7) and three Hey (Hey1, 2, L) genes have been identified.  Hes and Hey 
family members often act as transcriptional repressors by either binding to their 
target genes and recruiting histone modifying enzymes to silence gene 
transcription  or by associating with and rendering other bHLH transcription 




Notch signaling function in stem cells 
Notch signaling is believed to have two conserved functions in stem cells.  
First, notch signaling is involved in alternate fate determination whereby 
activation of the pathway promotes differentiation towards a certain cell fate from 
a common progenitor at the expense of the alternate fate (114).   This function is 
best exemplified in the development of sensory organ precursor cells in 
Drosophila.  A group of ectodermal cells with potential to become neurons arises 
as pre-neuronal clusters.  Some of these cells will express slightly higher levels 
of Delta and activate notch signaling in the neighboring cells.  Loss of function 
mutations in notch component genes result in the accumulation of neurons (so 
called neurogenic phenotype) indicating notch signaling inhibits neuronal 
differentiation (115-117).  Similar role for notch in the development of the 
vertebrate CNS has been shown in neural crest stem cells that have the potential 
to become either neurons or glia.  In these cells, notch signaling directs 
differentiation towards glia at the expense of neurons (118).   Notch signaling 
plays a similar role in other tissues including directing differentiation towards T-
cells at the expense of B-cells from a common lymphoid progenitor in the 
hematopoetic system and directing differentiation towards enterocytes at the 
expense of secretory goblet cells in the intestine (119-122).   
 A second conserved function of notch signaling is in progenitor pool 
maintenance, as a so called ‘gate keeper’ (119, 123).   In many instances, 
activating notch signaling increases the number of stem/progenitor cells.  For 
example, in the intestine, both enterocytes and goblet cells arise from a common 
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crypt progenitor cell.  Gut specific expression of NICD results in expansion of the 
crypt progenitor pool.  Similarly, notch inhibition using gamma secretase 
inhibitors or using tissue specific inactivation of CSL/RBP-J results in almost 
complete absence of crypt progenitors (124-126).  In the central nervous system, 
both gain of function and loss of function studies have shown that Notch 
signaling maintains undifferentiated progenitor cells.  Although recent studies 
show that functional Notch signaling may be disposable for maintaining HSC pool 
in adult mice in vivo (127), several gain and loss of function studies show that 
notch signaling can increase the self renewal capability of HSC in vitro (128-130).  
For instance, inhibiting notch signaling using dominant negative CSL/RBPJ or 
MAML or by γ-secretase inhibitor (GSI) treatment, results in accelerated HSC 
differentiation in vitro and loss of long-term repopulating capability in recipient 
animals in vivo (130).   
 
Notch signaling function in MSC lineage cells and bone 
  Genetic mutations or deletion of Jagged-1 results in the autosomal 
dominant disorder Alagille Syndrome (131).  This disorder is characterized by 
paucity of bile ducts in the liver and abnormal development of multiple organs 
including the heart, eye, kidney, face and vertebrae (132, 133).   The vertebral 
malformations are due to the role of Notch signaling in the somitogenesis from 
which vertebral bodies are derived.  Somites are derived from presomitic 
mesoderm by periodic activation of differentiation.  The notch target gene Hes-7 
is cyclically expressed in the presomitic mesoderm and activates lunatic fringe 
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which inhibits notch activation.  In the absence of this cyclic activation and 
inhibition of notch signaling, normal patterning of somites is lost and results in 
abnormal vertebrae patterning (134).  Patients with Alagille syndrome also have 
a decrease in bone mass and are at increased risk for fractures at young age 
(135).  It is not clear, however, whether the decrease in bone mass in Alagille 
syndrome is secondary to abnormalities in the liver and/or kidney or whether it 
arises primarily from defects in bone remodeling associated with altered notch 
signaling (136).   
 Recent studies using various mouse models have firmly established that 
notch signaling plays an important role in skeletal development.  Engin et al 
(2008) generated a Notch gain of function mouse by over-expressing NICD in 
osteoblast lineage cells using a 2.3 kb type I collagen promoter (Col2.3).  Long 
bones from these mice appear thickened and on histological examination have 
increased trabecular bone and increased osteoblast surface.  However, both 
trabecular and cortical bones were composed of immature woven bone, 
indicating that activating notch in committed osteoblasts either inhibits their 
terminal differentiation or affects their function.  Consistent with this hypothesis, 
calvarial cells from these mice were found to express higher levels of early 
osteogenic markers osterix, alkaline phosphatase and Col1A1, but expressed 
very low levels of the late differentiation marker osteocalcin (137).  In another 
study, Zanotti et al  used a 3.6kb fragment of the rat type I collagen promoter 
(Col3.6) to drive expression of NICD in osteoblasts and reported high levels of 
embryonic lethality, but the few mice that survived were small and had an 
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osteopenic phenotype with decrease trabecular bone that is due to decrease in 
osteoblast numbers (138).  The difference in phenotype of these two notch gain 
of function models is likely due to the difference in the pattern of expression of 
the two promoters used (Col2.3 and Col3.6) to drive NICD expression and 
suggests that the temporal activation of Notch signaling is important for its effect 
on osteogenic lineage cells.  Engin et al also generated a Notch loss of function 
mouse using Cre-loxP system to delete presenilins 1 and 2 by crossing 
presenillin1 fl/fl /presnillin2-/- mice with Col2.3-Cre mice.  Although no defect in 
osteoblast number or bone formation was observed, these mice develop 
osteopenia at 6 months of age due to an increase in osteoclast activity.   The 
increase in osteoclast activity was due to decreased production of 
osteoprotegerin by osteoblasts (137).  Osteoprotegerin is a decoy receptor that 
decreases osteoclast activity by antagonizing RANKL.     
 In a separate study, Hilton et al generated transgenic mice in which notch 
signaling is inhibited in earlier progenitors using Prx-1 promoter (139).  Prx-1 is 
expressed in mesenchymal condensations of developing bones starting at E10.5 
(140).  The investigators crossed presenillin1 fl/fl /presnillin2-/- mice with Prx-1Cre 
(PNN) mice to inactivate notch signaling in these early mesenchymal progenitors.   
Analysis of long bones of the resulting mice which lack both presenilins (PNN) at 
8 weeks of age revealed short bones and massive accumulation of trabecular 
bone.  Histomorphometric analysis revealed that the increase in bone mass was 
due to an increase in osteoblast number and not due to either an increase in 
osteoblast activity or decreases in osteoclast number or activity indicating the 
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notch signaling normally inhibits osteogenic differentiation of early progenitors.  
Investigation of CFU-F numbers as an indicator of progenitor numbers revealed 
that 8 week old PNN mice had markedly decreased CFU-F numbers indicating 
that notch signaling normally maintains mesenchymal progenitor numbers in vivo 
presumably by inhibiting their premature differentiation.  Interestingly, even 
though young PNN mice have markedly increased bone, they progressively lose 
bone mass as they age such that by 24 months they have ~10% of the bone 
mass when compared to controls. The authors concluded that notch signaling 
maintains the osteoprogenitor pool by preventing their premature differentiation.   
In addition to the increased osteoblast numbers and trabecular bone at 8 
weeks of age, PNN mice have a ‘wedge’ of cartilage, made up of hypertrophic 
chondrocytes that extends into the marrow space suggesting that notch signaling 
also affects chondrogenesis in the growth plate.  Indeed, analysis of the long 
bones from E18.5 embryos revealed that in addition to increase in the numbers 
of osteoblasts, PNN mice had significant expansion of hypertrophic chondrocytes 
in the bone marrow space.  The increase hypertrophic chondrocytes was due to 
an increase in proliferation and a delay in their terminal differentiation (139).  This 
embryonic phenotype in growth plate development complicates the interpretation 
of the increase in trabecular bone.  
 Both of these groups investigated the molecular mechanisms through 
which notch signaling affects MSC differentiation and found that Notch signaling 
inhibited transcriptional activity of Runx-2.   Engin et al reported physical 
interaction between NICD and Runx-2 while Hilton et al found that Hey-1 and 
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Hey-2 were responsible for the decrease in Runx-2 activity.   It is therefore 
possible that Notch signaling could act both in a CSL dependent mechanism 
through Hey-1 and Hey-2, and a CSL independent mechanism through NICD-
Runx-2 interaction to inhibit osteogenic differentiation.  Another proposed 
mechanism for the effects of notch signaling on osteogenic differentiation is 
through inhibition of Wnt signaling.  Over-expressing NICD inhibits Wnt-3a and 
BMP2 induced alkaline phosphate activity (a measure of osteogenic 
differentiation) in ST2 marrow stromal cell lines.  Although NICD had no effect on 
BMP2 induced SMAD or MAPK signaling, it was able to inhibit Wnt3a mediated 
β-catenin stabilization and reporter activity.  Restoring β-catenin levels did not 
rescue NICD mediated decrease in alkaline phosphate activity suggesting that 
the interaction between Wnt and Notch signaling occurs downstream of GSK-3β.  
siRNA mediated knock down of Hes-1 was able to partially rescue NICD 
mediated decreases in wnt signaling activation and decreased alkaline 
phosphatase activity indicating that Hes-1 is an important mediator of NICD in 
ST2 cells (141-143). 
In addition to the studies mentioned above, several in vitro studies have 
investigated the effects of notch signaling on the proliferation and differentiation 
of osteogenic cell lines.   Similar to its effect on ST2 cells, stable over-expression 
of a NICD in Kusa cells (murine MSC cell line) inhibits their osteogenic 
differentiation while transient over-expression of NICD in ST2 cells or ligand 
mediated activation in MC3T3E1 pre-osteoblast cell lines promotes their 
osteogenic differentiation (143-146).  These apparently conflicting results again 
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suggest that temporal expression and/or magnitude of activation may be 
important for the specific effect of notch signaling on MSC differentiation.  Indeed, 
notch signaling has been shown to have different effects on proliferation and 
differentiation of other cells types depending on the level of activation (147, 148).  
Notch signaling has also been shown to influence differentiation towards the 
chondrogenic and adipogenic cell fates.  Activating notch signaling in chick limb 
bud micro-mass cultures, in ATDC5 cells or in human MSC inhibits their 
chondrogenic differentiation (149, 150).  Similarly, activating notch signaling has 
been reported to inhibit adipogenic differentiation in 3T3-L1 preadipocytes (151).  
 
TSP2 Notch interaction 
 Activation of notch signaling can be regulated at multiple levels including 
transcription, post-translational modifications and stability and transport of either 
receptors or ligands (152).  In addition, recent studies have shown that 
components of the extracellular matrix, including CCN/NOV, SPARC, and 
thrombospondins can modulate notch activation in various cell types (153-156). 
 A study by Meng et al recently showed that either over-expressing TSP2 
cDNA or treatment with recombinant TSP2 but not TSP1 increases Jag-1 or Dll-4 
mediated activation of Hes-1 reporter activity in H460 lung cancer cell lines which 
selectively expresses Notch 3, but not Notch 1, 2 and 4.  Additionally, expression 
of notch target genes Hes-1, Hes-5 and Hey-1 in arterial smooth muscle cells, 
which also selectively express Notch-3, was found to be significantly increased in 
TSP2-null mice relative to wild type controls suggesting that TSP2 regulates 
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Notch-3 mediated signaling in-vivo.  In-vitro binding as well as co-
immunoprecipitation assays revealed that TSP2 can directly bind to Notch-3 and 
Jagged-1.   Furthermore, ligand treatment of H460 cells resulted in decreased 
cell proliferation and over-expressing TSP2 in these cells was able to potentiate 
ligand mediated inhibition of cell proliferation, indicating that TSP2 modulation of 
notch signaling likely plays a physiologically relevant function (157).   
 
Rationale/Hypothesis: 
   In conjunction with decreases in bone mineral density and changes in 
bone architecture, decreases in MSC number (as measured by CFU-F) and an 
increase in adipogenic differentiation is observed with aging.  These changes in 
MSC are believed to contribute to the pathogenesis of age associated 
osteoporosis.  However, our understanding of the mechanisms of how progenitor 
pools are maintained or alternate fate decisions between the osteogenic and 
adipogenic fates are made is limited. 
 TSP2 null mice have an increase in CFU-F at a young age and MSC from 
TSP2 null mice display a delay in mineralization therefore TSP2 is involved in 
both progenitor pool maintenance and osteogenic differentiation.  Whether TSP2 
plays a role in adipogenesis is however not known.  Furthermore, the molecular 
mechanisms through which TSP2 affects MSC are also unknown.   
Recent studies demonstrate that TSP2 can interact with Notch signaling 
and modulate it’s activation in various cell types.  Notch signaling has been 
shown to maintain MSC pool and inhibit osteogenic differentiation.  Because of 
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the demonstrated interactions between TSP2 and Notch activation, and the 
similar role TSP2 and Notch signaling appear to play in MSC pool maintenance 
and differentiation, we hypothesize that TSP2 effects on MSC are mediated 
through modulation of Notch signaling.   Our overall hypothesis is therefore, 
as a positive regulator of osteogenesis, TSP2 will inhibit adipogenic 
differentiation and that TSP2 effects on MSC proliferation and 
differentiation are mediated through modulation of notch activation. 
 
Dissertation Overview 
 In chapter 2, we will investigate whether TSP2 plays a role in adipogenic 
differentiation in vitro and in vivo.  In chapter 3, we will investigate whether notch 
signaling regulates proliferation and osteogenic and adipogenic differentiation of 
primary MSC in vitro and whether canonical notch signaling is required for MSC 
pool maintenance and bone formation in vivo.  Finally, in the chapter 4, we will 
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Osteoporosis is a disease characterized by osteopenia and increased risk 
of bone fracture.  Along with a decrease in bone mass, an increase in bone 
marrow adiposity is observed in osteoporosis patients and is believed to 
contribute to the pathogenesis of the disease (11, 55-57).  Although the 
mechanism for increased adipocytes is currently unknown, one hypothesis is that 
there is a shift in differentiation of mesenchymal stem cells (MSC) to adipocytes.   
MSC are precursor cells that give rise to osteoblasts, adipocytes and 
chondrocytes.   Many growth factors and cytokines as well as systemic 
hormones that regulate MSC differentiation have been identified, and 
interestingly, in most instances factors that promote osteogenic differentiation 
also appear to inhibit adipogenic differentiation lending support to the 
‘differentiation shift’ hypothesis (59-61).  
The process of adipogenic differentiation is highly-coordinated and is 
characterized by distinct changes in transcription factor expression and 
alterations in genes associated with fatty acid metabolism and growth factor 
 
 26 
activity.  Adipogenic induction results in up regulation of transcription factors in 
the C/EBP family including C/EBPα and C/EBPβ.  These transcription factors in 
turn activate transcription of PPAR-γ, often referred to as a master regulator of 
adipogenesis as its activity is both necessary and sufficient for adipogenic 
differentiation.  PPAR-γ then orchestrates expression of genes required for fatty 
acid metabolism and adipocyte maturation (51-53).  
In addition to changes in transcription factors, there are distinct changes in 
the expression of extracellular matrix (ECM) proteins that occur with the 
development of mature adipocytes (85, 158).  The function of the ECM in 
regulating adipogenic differentiation is however not well-understood.   Recent 
studies have demonstrated that adhesive substrates promote osteogenesis and 
inhibit adipogenesis.  We have recently reported that heparin promotes 
adipogenic differentiation by inhibiting focal adhesion formation (84).   ECM 
proteins function not only for adhesion and structural integrity, but also bind to 
growth factors and interact with cell surface receptors not required for adhesion.  
For example, mice deficient in the ECM protein, secreted protein acidic and rich 
in cystine (SPARC), exhibit an increase in subcutaneous and visceral fat due to 
both an increase in adipocyte numbers and adipocyte size (159).  In vitro, 
adipogenic differentiation is enhanced in stromal cells isolated from bone marrow 
as well as white adipose tissue (WAT) of SPARC null mice.  The molecular 
mechanism through which SPARC affects adipogenesis appears to be through 
stabilization of focal adhesions and promotion of integrin linked kinase activity 
which in turn results in stabilization of β-catenin.  β-catenin is a component of the 
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Wnt signaling pathway that is known to inhibit adipogenic differentiation (160).  
Intriguing studies recently showed that osteocalcin, an ECM protein exclusively 
produced by osteoblasts, can regulate energy metabolism by acting on distally 
located pancreatic islet cells (161, 162).  These findings demonstrate that ECM 
can influence adipogenesis through diverse mechanisms.   
Thrombospondin-2 (TSP2) is a large multi-modular protein that belongs to 
a group of ECM proteins referred to as matricellular proteins— a group of 
proteins, including SPARC, that interact with cells and other structural ECM 
proteins but by themselves play minimal structural role (99).  TSP2 has been 
shown to interact with multiple cell receptors, growth factors and ECM proteins 
and regulates apoptosis, cell proliferation and adhesion.  TSP2 is highly 
expressed in MSC and other mesenchymal derived tissues including adipose 
tissue (51-53).  Previous work has shown that, in mouse adipose tissue, TSP2 
mRNA is decreased in the mature adipocyte fraction when compared to the 
stromal-vascular fraction which contains undifferentiated stem and progenitor 
cells suggesting that TSP2 expression decreases with adipogenic differentiation 
(163). 
Previous studies have also shown that TSP2 inhibits bone marrow derived 
MSC proliferation.  In addition, TSP2-null MSC display a delay in matrix 
mineralization indicating that TSP2 promotes osteogenic differentiation in vitro 
(100, 101).  However, whether TSP2 plays a role in adipogenic differentiation is 
unknown.  Because of the reciprocal relationship between osteogenic and 
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adipogenic fates, we hypothesized that as a protein that promotes osteogenic 
differentiation, TSP2 will inhibit adipogenic differentiation.   
Herein we report that MSC isolated from TSP2 null bone marrow and 
WAT display an increase in lipid accumulation.  TSP2 null mice are heavier than 
wild type controls due to an increase in adipose tissue.  Finally, consistent with 
its role in promoting osteogenesis and decreasing adipogenesis, TSP2 
expression increases during osteogenic differentiation and is inhibited during 
adipogenesis.   
 
Materials and Methods 
Mice:  All procedures were approved by the institutional animal care and use 
committee. TSP2-null mice have been described previously and were generated 
by targeted disruption of the Thbs2 gene which results in a functional TSP2-null 
phenotype (101).  Coisogenic wild-type 129/SvJ mice were used as controls for 
comparison.  For high fat diet studies, one month old TSP2-null and wild-type 
control mice were fed control or high fat chow (D12450B or D12451, respectively, 
Research Diets Inc., New Brunswick, NJ) for 5 months.  Mice  were weighed 
weekly and at the end of the 5 month study period, they were anesthetized with 
pentobarbital sodium (50 mg/kg BW i.p.), and body composition was measured 
using dual-emission x-ray absorptiometry (DEXA) (PIXImus DEXA, General 
Electric, Madison, WI).  Mice were then euthanized and subcutaneous and 




Bone marrow MSC isolation:  Whole bone marrow was harvested from femora 
and tibiae of three to four month old TSP2-null and wild type control mice as 
previously reported (101).  Single cell suspensions from three mice were pooled, 
and then plated onto four 100mm tissue culture plates in MSC media (alpha-
minimum Eagle’s medium supplemented with 10% fetal bovine serum, 2 mM L-
glutamine, 25µg/mL sodium ascorbate, and 100U/mL penicillin and 100µg/mL 
streptomycin).  Cells were cultured for 8 to 10 days with half the media being 
replaced four days post plating, and every three days until harvest.   When 
cultures reached 80% confluence, cells were trypsinized, and then plated onto 
12-well tissue culture plates for differentiation experiments.   
 
Stromal vascular fraction (SVF) cell isolation:  Perilumbar fat pads from 3 to 5 
mice were minced then digested for 30-60 minutes at 37°C with 2.5mg/ml 
collagenase II (Sigma-Aldrich).  The digest was filtered through a 70μm filter and 
centrifuged at 500g for 6 min to pellet the SVF cells. The stromal vascular cells 
were then plated onto 10cm tissue culture plates in SVF media (Dulbecco’s 
modified eagle medium (DMEM) + 10% fetal bovine serum + 100U/mL penicillin 
and 100µg/mL streptomycin) and passaged when they reached 80% confluence.  
Third passage cells were used for all experiments.   
 
Cell Culture and treatments:  
For adipogenic differentiation, 1X105 primary bone marrow derived MSC or 
5X104 ST2 and SVF cells were plated into each well of 12-well tissue culture 
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plates.  Three days post plating, bone marrow derived MSC and ST2 cells were 
treated with induction media (MSC media containing MDI; 57μM isobutyl-
methylxanthine, 1μM dexamethasone, and 1μg/mL insulin or MDI/T; MDI and 
5μg/ml troglitazone) for three days then maintained in MSC media containing 
1μg/mL insulin for the remaining duration of the experiments.   SVF cells were 
induced two days post plating with the same induction cocktail in SVF media then 
were switch and maintained in  SVF media with 1μg/mL insulin two days post 
induction.  Cells were stained with Oil Red-O and DAPI and five representative 
images at 40X magnification were captured.  Cells staining positive for DAPI and 
Oil Red-O were counted and compared to total DAPI positive cells. Oil Red-O 
was then extracted and quantified by measuring absorbance at 540nm in a 
Varioscan spectrophotometer (Thermo Fisher Scientific, Waltham, MA USA).  
For osteogenic differentiation, ST2 cells were treated and maintained in MSC 
media containing 10nM BMP2, 25μg/mL sodium ascorbate and 10mM β-glycerol 
phosphate. 
 For pharmacomimetic and inhibitor studies, 3T3-L1 cells were plated at a 
density of 1X105 cells per well into each well of a 6 well tissue culture plate in L1 
media (DMEM, 10% fetal bovine serum, 100U/mL penicillin, 100ug/mL 
streptomycin) and cultured for 3 days.  Cells were then treated with the indicated 
combinations and concentrations of drugs for 24 hours.    
 
Quantitative RT-PCR: RNA was extracted using RNeasy RNA extraction kit 
(QIAGEN) according to the manufacturer’s instruction and 1μg of total RNA was 
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reverse transcribed in a 30μL reaction.  2μL of the cDNA generated was used for 
quantitative real-time PCR reaction using SybrGreen for detection on either a 
MJR Opticon or an ABI 7500 Fast.  Relative change in expression of genes of 
interest was determined using the 2ΔΔC(T) method using β-actin expression as an 
endogenous control.  
 
Western Blot Analysis:  Equal volumes of media collected at the indicated time 
points were resolved on 8% SDS-PAGE gels, transferred onto nitrocellulose 
membranes and probed with a mouse TSP2 polyclonal antibody.  After 
incubating with HRP-conjugated secondary antibody, membranes were 
developed with ECL Chemiluminescent reagent.   
 
Statistical Analysis:  Student’s t-tests were used to compare means between 
TSP2-null and wild type and between treated groups and untreated controls. 
 
Results 
TSP2-null bone marrow MSC exhibit increased lipid accumulation. 
 TSP2-null MSC display a delay in osteogenic differentiation.  To determine 
whether TSP2 also plays a role in adipogenic differentiation, first passage bone 
marrow-derived MSC from TSP2-null and wild-type control mice were induced to 
undergo adipogenic differentiation using MDI or MDI/T and extent of adipogenic 
differentiation was evaluated at 10 days post induction by staining intracellular 
lipid droplets with Oil Red-O and then measuring total extracted Oil Red-O using 
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spectrophotometry.  TSP2-null MSC showed 24% and 25% more Oil Red-O 
incorporation than wild-type controls at 4 and 10 days post-adipogenic induction, 
respectively (Figure 2.1 A-C).  Evaluation of adipogenic marker gene expression 
showed expected increases in C/EBP-α, PPAR-γ or FABP-4 expression following 
adipogenic induction at day 4 and 10 post-induction.  However, there were no 
differences between TSP2-null and wild type MSC in any of the treatment groups 
at 4 days post adipogenic induction.  At 10 days post induction, a 37% increase 
in C/EBP-α expression in MDI/T induced and a 15% increase in FABP-4 
expression was detected in un-induced TSP2-null MSC when compared to wild 
type MSC that received the same treatments.  There was no significant 
difference in PPAR-γ expression between TSP2-null and wild-type MSC at 10 
days post adipogenic induction (Figure 2.2).  The increase in lipid accumulation 
in TSP2-null MSC without significant increases in C/EBP-α, PPAR-γ or FABP-4 
expression suggests that TSP2 does not directly affect adipogenic commitment 
but may act through other mechanisms, such as inhibition of cell proliferation 
and/or fatty acid uptake, to influence lipid accumulation.  
 
TSP2-null mice exhibit an increase in adipose tissue. 
 Since TSP2-null marrow MSC showed increased lipid accumulation in 
vitro, we asked whether TSP2 regulates adipose tissue development in vivo.  
Age and gender matched six-week old TSP2-null and wild type control mice were 
placed on either control or high fat diet and were weighed weekly for 22 weeks 
(Figure 2.3).  TSP2-null female mice gained significantly more weight than wild-
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type control female mice under control diet.  The difference in weight became 
statistically significant at 17 weeks and was greatest at 22 weeks with TSP2-null 
mice weighing 30% more than wild-type controls.  Interestingly, there was no 
significant difference in weight between TSP2-null and wild type control male 
mice fed the control diet or in either male or female TSP2-null and wild type 
control mice fed a high fat diet (Figure 2.3 A,B). 
To determine whether the increase in weight in TSP2-null mice was due to 
an increase in adipose tissue, we measured body composition of TSP2-null and 
wild-type mice at the end of the 22 week study period using dual energy X-ray 
absorptiometry (DEXA) (Figure 2.4).  The percentage of total body fat was 
significantly higher in TSP2-null female mice on control diet when compared to 
gender matched wild-type controls.  No appreciable difference was detected in 
percent body fat in male mice fed control diet or male or female mice fed high fat 
diet (Figure 2.4 A,B).  There was no appreciable difference in either lean body 
mass or bone mass between male or female TSP2-null or wild type control mice 
fed control or high fat diet (data not shown).  These results are consistent with 
results that show significant differences in weight between TSP2-null and control 
mice for female mice and suggest that the explanation for increased body mass 
in TSP2-null mice is increased adipose tissue.    
To determine whether the increase in adipose tissue in TSP2-null mice 
occurs at specific sites, subcutaneous fat pads from interscapular and perilumbar 
regions, visceral fat pads from perirenal and reproductive (ovarian or testicular) 
regions, as well as brown fat and skin were isolated and weighed (Figure 2.5).  
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There was a 2.7 fold increase in both perilumbar and interscapular 
(subcutaneous) fat pads and 1.5 fold increase in skin weight in female TSP2-null 
mice on control diet when compared to wild type controls.  There was no 
statistically significant difference in visceral (perirenal and reproductive) or brown 
fat pad weights in either female or male TSP2-null and wild type control mice 
(Figure 2.5 A).  With the exception of a decrease in ovarian fat pad weight in 
TSP2-null mice, there was no difference in fat pad or skin weights between 
TSP2-null and wild type control mice fed a high fat diet (Figure 2.5 B).   Taken 
together, these results indicate that TSP2-null female mice weigh more than wild 
type controls due to an increase in weight of skin and subcutaneous fat.  
 
Adipose tissue derived MSC from TSP2-null mice show increased 
proliferation and lipid accumulation. 
The stromal vascular (S/V) fraction of white adipose tissue contains cells with 
similar differentiation potential as bone marrow derived MSC.  To determine 
whether the increase in adiposity in TSP2-null mice is due to TSP2 having an 
effect on proliferation and/or adipogenic differentiation of these adipose tissue 
derived MSC (AdMSC), cell proliferation and differentiation were examine in S/V 
cells isolated from perilumbar fat pads of TSP2-null and wild type control mice. 
To determine whether TSP2 plays a role in AdMSC proliferation, TSP2-null and 
wild type AdMSC were plated at equal density then were trypsinized and counted 
every 24 hours for 5 days.  The total number of TSP2-null cells was 1.3, 3.3, 4.2 
and 4.5 fold higher than wild type controls at 48, 72, 96 and 120 hours, 
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respectively.  This is consistent with published data on marrow-derived TSP2-null 
MSC which show increased proliferation relative to wild type.   
 
To evaluate whether TSP2 plays a role in adipogenic differentiation of AdMSC, 
TSP2-null and wild type AdMSC were induced to undergo adipogenic 
differentiation using MDI or MDI/T and extent of lipid accumulation at 4, 7, and 14 
days post induction was measured using Oil Red-O incorporation (Figure 2.7).   
A statistically significant increase in Oil Red-O staining was observed in TSP2-
null AdMSC induced with MDI/T at days 4 and 7 and in MDI induced cells at day 
7.  There was also significantly more Oil Red-O incorporation in un-induced 
TSP2 null AdMSC at days 4 and 14 (Figure 2.7 A).  To determine whether the 
increase in Oil Red-O staining in TSP2-null cells was due to an increase in cell 
number, the number of Oil Red-O staining cells was counted and normalized to 
the total number of cells as determined by counting the number of DAPI stained 
nuclei.  Similar to Oil Red-O absorbance findings,  the number of  Oil Red-O 
positive cells normalized to the total number of cells was significantly increased 
in MDI/T induced TSP2 null AdMSC at days 4 ,7 and 10, in MDI treated cells at 
day 7 and in un-induced controls at day 4 and day 7 (Figure 2.7 B).  Taken 
together, these results show that in the absence of TSP2 there is increased lipid 
accumulation in AdMSC and its effect on lipid accumulation in these cells is 




TSP2 expression is differentially regulated during osteogenic and 
adipogenic differentiation 
 TSP2 is expressed at lower levels in mature adipocyte fractions when 
compared to the stromal and vascular fractions of adipose tissue suggesting that 
TSP2 expression may be down-regulated during adipogenic differentiation (163).  
To better understand the regulation of TSP2 expression during MSC 
differentiation, bone marrow stromal cell derived ST2 cell lines were induced to 
undergo osteogenic and adipogenic differentiation and  TSP2 mRNA as well as 
protein secreted into the media was examined at 1, 3, 6, 9, and 12 days post 
induction (Figure 2.8).  TSP2 mRNA levels initially decreased at day 1 post 
osteogenic induction but gradually increased such that at days 6, 9 and 12 there 
were 1.7, 3.8, and 6.9 fold increases in TSP2 mRNA expression in osteogenic 
induced cells relative to un-induced controls, respectively (Figure 2.8 A).  TSP2 
mRNA decreased to 30% of un-induced controls by day 1 following adipogenic 
induction and remained at that low level at days 3, 6, 9 and 12 post induction 
(Figure 2.8 B).  To determine whether the differences in TSP2 mRNA expression 
translated to the protein level, media was collected at the time of RNA harvest 
and TSP2 protein present in the media was analyzed by western blot.  A similar 
pattern of gradual increase with osteogenic induction and rapid and sustained 
decrease with adipogenic induction relative to un-induced control cells was 
observed in TSP2 protein secreted into the media (Figure 2.8 C).  Therefore, 
TSP2 expression at both the mRNA and protein levels, increases with osteogenic 




Components of adipogenic induction cocktail have additive effects in 
down-regulating TSP2 expression.  
To begin to understand the molecular mechanism of TSP2 down-
regulation during adipogenesis, we evaluated the influence of the components of 
the adipogenic cocktail in the down-regulation of TSP2 in 3T3-L1 cells—a pre-
adipocyte cell line in which the adipogenic differentiation program has been more 
thoroughly characterized (Figure 2.9) (164).  Similar to ST2 cells, the 
combination, isobutyl-methylxanthine (IBMX), dexamethasone, and insulin (MDI) 
had profound effects in down-regulating TSP2 expression in 3T3-L1 cells 
reducing it to 12.6% of un-induced controls at 24 hours post treatment.  When 
used alone, IBMX, dexamethasone and insulin reduced TSP2 expression to 46%, 
51% and 64% of un-induced controls, respectively.  Using two of these agents in 
combination resulted in greater decrease in TSP2 expression than using each 
one alone indicating that IBMX, dexamethasone and insulin have additive effects 
in down regulating TSP2 expression (Figure 2.9 A).   
IBMX is a phosphodiesterase inhibitor that acts to increase levels of cAMP 
therefore we examined the relative importance of the cAMP/PKA pathway in 
regulating TSP2 expression.  To determine whether PKA activity is required for 
down-regulating TSP2 expression, we treated cells with H89, which blocks PKA 
activity in the presence or absence of the IBMX, Forskolin (a PKA activator), and 
8-Br cAMP (a cAMP analog).  Treatment with IBMX or Forskolin individually 
reduced TSP2 expression to 51% and 61% of untreated controls, respectively, 
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and when used in combination, they reduced TSP2 levels to 12.4% of untreated 
controls suggesting that these two agents have a synergistic effect on down-
regulating TSP2 expression.  Although 8-Br cAMP, used at 0.5mM dose did not 
significantly reduce TSP2 expression, it acted synergistically with IBMX to reduce 
TSP2 mRNA to 14.7% of untreated controls.  H89 by itself did not affect TSP2 
expression but it completely abrogated the effect of IBMX and Forskolin on 
down-regulating TSP2 expression (Figure 2.8 B). To determine whether 
increasing cAMP levels is sufficient to inhibit TSP2 expression, cells were treated 
with increasing doses of 8-Br cAMP for 24 hours and TSP2 mRNA levels were 
analyzed.  Although treating cells with 0.5mM of 8-Br cAMP did not result in a 
statistically significant decrease in TSP2 expression, 2.5mM and 12.5mM of 8-Br 
cAMP reduced TSP2 mRNA to 22.4% and 11.5% of untreated controls, 
respectively, indicating that increasing cAMP levels is sufficient to down regulate 
TSP2 expression in 3T3-L1 cells. 
 
Discussion 
We have previously shown that TSP2 promotes osteogenic differentiation 
of bone marrow derived MSC.  Because of the reciprocal relationship between 
osteogenic and adipogenic cell fates, in this study, we examined the role of TSP2 
in adipogenesis in vitro and in vivo.   
Our results show that bone marrow derived TSP2-null MSC show an 
increase in lipid accumulation when compared to wild type controls.  Surprisingly, 
there was no significant increase in expression of PPAR-γ, a key transcription 
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factor believed to be a master regulator of adipogenesis, at either day 4 or day 
10 post adipogenic induction.  C/EBP-α, an early adipogenic transcription factor 
that acts to up-regulate PPAR-γ, only showed a slight increase in expression at 
day 10 after peak expression in all three marker genes examined has occurred.  
The lack of major differences in gene expression of these two transcription 
factors between TSP2-null and wild type MSC suggests that TSP2 decreases 
lipid accumulation in bone marrow MSC not by directly regulating adipogenic 
differentiation but rather though an independent mechanism.  Similar to bone 
marrow MSC, TSP2-null adipose tissue derived MSC showed an increase in 
proliferation and lipid accumulation.  By normalizing the number of lipid droplet 
containing adipocytes to the total number of cells, we found that TSP2 decreases 
lipid accumulation in AdMSC independent of its effect on cell proliferation.   
The cellular and molecular mechanisms through which TSP2 influences 
adipogenesis were not investigated in this study, but there are several possible 
considerations.  First, because TSP2 binds to CD36, Fatty Acid Transporter, 
which is a Class B Scavenger Receptor, TSP2 could interfere with CD36 uptake 
of long-chain fatty acids and disrupt adipogenesis (165).  Alternatively, it has 
been proposed that pre-adipocytes need to progress through clonal expansion 
early in adipocyte differentiation and TSP2, as a potent inhibitor of cell 
proliferation, may play an inhibitory role in this processes (166).  Intriguing recent 
work has shown that TSP2 directly interacts with Notch, and depending on the 
cell-type examined may either promote or inhibit Notch signaling (156).  Notch 
 
 40 
signaling has been shown to regulate adipogenesis and TSP2 could also act 
through notch to decrease adipogenesis (167). 
We also examined whether TSP2 plays a role in adipose tissue 
development in vivo and found that TSP2-null female mice weigh more than age 
and gender matched wild type control mice.  The increase in weight appeared to 
be due to an increase in adipose tissue and skin.  One primary function of 
adipose tissue is to store excess energy in the form of neutral triglycerides.  
Excess energy can occur in a closed system either secondary to a decrease in 
energy expenditure or an increase in food intake.  Future studies should examine 
whether an increase in food intake or a decrease in energy expenditure enables 
an increase in adipose tissue in TSP2-null female mice.     
The effects of TSP2 on body weight and adipose tissue development were 
only observed in female mice suggesting that TSP2 may alter adipose tissue 
regulation by female sex hormones.  Interestingly, the absence of TSP2 has 
been shown to protect against ovariecomy-induced bone loss (168).  It is well 
known that estrogen, produced by the ovaries, is a major regulator of adipose 
tissue development (169).  It will be interesting to determine whether TSP2 can 
modulate the actions of estrogen or other female sex hormones on adipose 
tissue development.   
We also examined TSP2 expression during MSC differentiation and found 
that consistent with a role in promoting osteogenic differentiation and decreasing 
adipogenesis, TSP2 expression is up-regulated during osteogenic differentiation 
and is inhibited during adipogenic differentiation.  The observation that TSP2 
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down-regulation occurs within 24 hours of adipogenic induction suggests that 
down regulation of TSP2 expression may be important for early adipocyte 
development and maturation.  We also found that activation of cAMP dependent 
PKA pathway during adipogenic differentiation plays a major role in down-
regulating TSP2-expression.  Although their mechanisms were not examined 
further in this study, dexamethasone and insulin used in the adipogenic induction 
cocktail were also found to play a role in down-regulating TSP2 expression.   
Here we have described an inhibitory role for TSP2 on adipogenesis in- 
vitro and in vivo and have characterized the changes that occur in TSP2 
expression levels with MSC differentiation.  Future studies will address the 
mechanisms through which TSP2 affects adipose tissue development at the 
molecular, cellular and whole animal level.   
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Figure 2.1  
 




























Figure 2.1 TSP2 Inhibits lipid accumulation in bone marrow MSC.  MSC 
isolated from bone marrow of wild-type and TSP2-null mice were induced to 
undergo adipogenic differentiation using MDI or MDI/T then stained with Oil Red-
O at 4 and 10 days post induction.   Image of representative Oil Red-O stained 
plate at 10 days post adipogenic induction (A) and representative 10X 
magnification images of cells induced with the indicated treatments (B) are 
shown.  To quantify lipid accumulation, Oil-Red O was extracted from MDI/T 
induced cells at 4 and10 days post adipogenic induction and absorbance was 
measured at 540 nm (C).  The results shown are representative of two 
independent experiments each performed in duplicate. For each experiment 
MSC were obtained from 3 wild type and 3 TSP2-null mice and whole marrow 
pooled to yield MSC. (Error bars represent standard deviation.  # = TSP2-null 



































































Figure 2.2  Minor differences in expression of adipogenic marker genes 
exist between TSP2-null and wild-type MSC.   Bone marrow derived MSC 
from TSP2-null and wild-type control mice were induced to undergo adipogenic 
differentiation with either MDI or MDI/T.  Cells were harvested at 4 and 10 days 
post adipogenic induction and expression of adipogenic differentiation marker 
genes C/EBP-α, PPAR-γ, and FABP-4 was analyzed by qPCR.  The results 
shown are averages of two independent experiments each performed in 
duplicate.  Error bars represent standard deviation.  # =TSP2-null significantly 
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Figure 2.3 TSP2-null mice are heavier than wild-type control mice but do 
not gain appreciably more weight on high fat diet.   6 week old TSP2-null and 
wild-type mice from at least four litters were randomly placed on either a control 
or a high fat diet for 22 weeks. Mice were weighed weekly and the average body 
weight for each group (+ SEM) at each time point is depicted in the graphs.   (A) 
Control diet:  Female (wild-type n=5, TSP2-null n=5); Male (wild-type n=8; TSP2-
null n=6)  (B) High calorie diet: Female (wild-type n=5, TSP2-null n=5); Male 
(wild-type n=9; TSP2-null n=6). A statistically significant increase in body weight 
was observed at weeks 17 through 22 for female TSP2 null mice fed the control 
diet relative to wild type control mice on the same diet. (# = TSP2-null 
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Figure 2.4 TSP2-null female mice on control diet have an increase in 
adipose tissue.  Total body composition of TSP2-null and wild-type control mice 
fed either a control diet (A) or a high fat diet (B) for 22 weeks starting at 6 weeks 
of age was measured using dual-emission x-ray absorptiometry (DEXA).  The 
percentage of fat tissue is depicted as mean + SEM . Wild-type (control diet, 
male n=7, female n= 5) and high calorie diet (male n=9, female n= 5)) and TSP2-
Null (control diet male n=6,  female n= 5 and high fat diet male n=6, female n= 5);  
# = significantly different from wild type; p < 0.05.  There was no significant 
difference in lean mass or bone mass percentages between TSP2-null and wild-






























































Figure 2.5  Subcutaneous fat pads and skin from TSP2-null mice weigh 
more that wild-type controls.  Fat pads and skin from TSP2-null and wild type 
mice fed either control (A) or high fat diet (B) were harvested and weighed. A 
statistically significant increase in perilumbar and interscapular (subcutaneous) 
fat pad as well as skin weight was observed in female TSP2-null mice on control 
diet.  Values are mean + SEM.  Wild type (control diet male n=7, female n= 5 and 
high calorie diet male n=9, female n= 5) and TSP2-null (control diet male n=6, 
female n= 5) and high calorie diet male n=6, female n= 5); # = TSP2-null 
































































































































































Figure 2.6 Adipose tissue derived MSC from TSP2-null mice show 
increased proliferation.  Adipose tissue derived MSC were plated at 50,000 
cells/well in 12 well tissue culture plates then were trypsinized and counted at the 
indicated time points.  Statistically significant increase in TSP2-null cell numbers 
relative to wild type controls was observed at 48, 72, 96, and 120 hours post 
plating.  Values shown are mean + SEM of five independent experiments 
conducted on five independent age-matched cell harvests.  # = TSP2-null 

































































Figure 2.7 TSP2-null adipose tissue derived MSC show increased lipid 
accumulation.  Adipose tissue derived MSC were induced to undergo 
adipogenesis with either MDI or MDI/T then were fixed and stained with DAPI 
and Oil Red-O at days 4, 7 and 14 post induction.  Five representative images 
were captured at 40X magnification from each well then Oil Red-O was extracted 
and quantified by measuring absorbance at 540 nm (A).  The number of Oil Red-
O stained cells in captured image were counted and normalized to the total 
number of cells (DAPI staining nuclei) to account for differences in cell 
proliferation between TSP2 null and wild type MSC (B).   Values are mean + 
SEM of 3 independent experiments from 3 independent harvests.  # = TSP2-null 










































































































































Figure 2.8  TSP2 expression is reciprocally regulated during adipogenic 
and osteogenic differentiation.  ST2 cells were induced to undergo osteogenic 
and adipogenic differentiation for 12 days.  Cells were harvested at the indicated 
time points following induction and TSP2 mRNA expression relative to un-
induced control cells harvested at the same time was measured by quantitative 
real-time PCR (A,B).  Media was also collected at the indicated time points and 
the amount of TSP2 protein secreted into the media was estimated by resolving 
equal volumes of media on SDS-PAGE gels and western-blot analysis (C).  
Results shown are mean + S.D. of two independent experiments each done in 
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Figure 2.9 
 































Figure 2.9  Components of adipogenic induction cocktail additively down-
regulate TSP2 expression.  Confluent 3T3-L1 cells were treated with the 
indicated combinations of adipogenic induction cocktail for 24 hours then TSP2 
mRNA was measured using qPCR.  (M, IBMX: D, Dexamethasone:  I, Insulin) (A)  
3T3-L1 cells were treated with the indicated combination of IBMX (100μM), 
forskolin (10μM),  8-Br cAMP (0.5mM) or H89 (20μM)  for 24 hours and TSP2 
mRNA levels were analyzed by qPCR (B).  3T3-L1 cells were treated with either 
100mM IBMX or increasing doses of 8Br-cAMP (0.5mM, 2.5mM and 12.5mM ) 
for 24 hours and TSP2 expression was analyzed by qPCR (C).  Data shown are 
mean + S.D. of two independent experiments each done in duplicate. (# = TSP2-






















































































































































MSC FATE DETERMINATION BY NOTCH SIGNALING 
 
Introduction 
 Bone remodeling is a complex process by which old bone is resorbed and 
new bone is formed through the actions of osteoclasts and osteoblasts.  Under 
normal physiological conditions, bone resorption and bone formation are 
maintained in homeostasis (1, 2).  Imbalances from either a net decrease in bone 
formation or a net increase in bone resorption result in decreased bone mass 
(osteopenia).  If osteopenia is severe enough, it results in the clinical condition 
osteoporosis which is characterized by increased risk of bone fracture.  Although 
the causes of osteoporosis are multi-factorial and include genetic and 
environmental causes, increased age is one of the most significant risk factors.  
In age associated (senile) osteoporosis, there is a decrease in both bone 
formation and bone resorption but the decrease in bone formation is greater than 
the decrease in bone resorption, therefore age associated osteoporosis is 
primarily a disease of decreased bone formation (6-11).   
 Bone is formed by osteoblasts derived from mesenchymal stem cells 
(MSC).  MSC are a mixed population of cells that are isolated from bone marrow 
by their ability to strongly adhere to tissue culture plastic.  When whole bone
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marrow is plated at low density, MSC form single cell derived fibroblastic colonies 
(CFU-F).  The number of CFU-F correlates with the number of osteoprogenitor 
cells in vivo and is commonly used to estimate the number of progenitor cells that 
are present in vivo.  CFU-F numbers decline with ageing which suggests that a 
decline in osteoprogenitor numbers may contribute to age associated decrease 
in bone formation (170, 171).   
In addition to a decrease in bone mass, an increase in bone marrow 
adiposity is also observed in osteoporosis patients and in other bone loss 
conditions (55, 57).  Since bone marrow adipocytes are also derived from MSC, 
a shift in differentiation from osteoblast to adipocyte lineage has also been 
proposed as another possible mechanism for age associated decrease in bone 
formation.  However, mechanisms responsible for maintaining MSC number in 
vivo and determining osteogenic vs. adipogenic fate are not well understood.   
 Notch is a highly conserved cell-to-cell signaling mechanism that appears 
to have two conserved functions in stem cells.  First, notch signaling directs 
differentiation of stem cells towards one cell fate at the expense of an alternative 
fate.  For instance, activation of notch signaling in neural stem cells results in 
their differentiation to glia at the expense of neurons (112).  Similarly, in the 
hematopoetic system, notch directs differentiation of common lymphoid 
progenitors towards T-cells at the expense of B-cells (172).  Second, Notch 
signaling maintains the stem/progenitor cell pool in many organs often by 
inhibiting differentiation.  For example, in skeletal muscle, activation of notch 
signaling inhibits differentiation of muscle progenitors and interfering with the 
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pathway results in excessive myogenic differentiation and depletion of the 
progenitor cell pool.  Stem cell depletion in notch loss of function models and/or 
stem cell expansion in notch gain of function studies have been reported in stem 
cells in the intestine, central nervous and hematopoetic systems (117-120).  
Notch receptors are single pass transmembrane proteins that interact with 
ligands of the delta/serrate (delta-like and Jagged) family.  Ligand binding to 
receptor results in a series of enzymatic cleavages that ultimately result in the 
release of the notch intracellular domain (NICD) into the cytoplasm.  The first 
cleavage is mediated through ADAMS/TACE family of membrane bound 
metaloproteinases and results in the removal of the notch receptor ectodomain.  
The second cleavage, mediated by a multi-protein γ-secretase enzyme complex 
which includes presenilins (PSN1 and 2) as its catalytic unit, results in the 
release of NICD from the cell membrane into the cytoplasm.  NICD then 
translocates to the nucleus and binds to the DNA binding transcription factor CSL 
(for CBF1, Suppressor of Hairless, or Lag-1).  In the absence of NICD, CSL 
binds to promoter elements in association with co-repressors and acts to inhibit 
target gene expression.  NICD binding to CSL displaces co-repressors and 
recruits the transcriptional co-activator Mastermind Like-1 (MAML).  Formation of 
NICD/CSL/MAML complex is required for recruitment of the basic transcriptional 
machinery to initiate transcription of notch target genes (104-110).  The best 
characterized notch targets are the beta-helix-loop-helix transcription factors of 
the Hes and HERP/Hey family (111).  In mammals 4 members of the Hes family 
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(Hes-1, 3, 5 and 7) and 3 members of the Hey family (Hey-1, 2 and L) have been 
shown to be direct targets of CSL mediated “canonical” notch signaling (111).   
 Several lines of evidence indicate that notch signaling plays an important 
role in development and maintenance of bone.  A loss of function mutation in the 
notch ligand Jagged-1 in humans results in Alagille Syndrome; an autosomal 
dominant disorder characterized by abnormalities of the bile duct, heart and 
vertebrae (173).  Mutations in Dll-3 in mice has also been reported to cause 
vertebral malformation indicating that notch signaling plays a role in vertebral 
segmentation during embryonic development (174).  
 Several studies that have investigated the role of notch signaling on MSC 
proliferation and differentiation in vitro have reported conflicting results.  For 
instance, while stable over-expression of a constitutively active notch intracellular 
domain (NICD) in ST2 or Kusa cells (both are murine MSC cell lines) inhibits 
their osteogenic differentiation, transient over-expression of NICD in ST2 cells or 
ligand mediated activation in MC3T3E1 pre-osteoblast cell lines promotes their 
osteogenic differentiation (143-146).  Similarly, over-expressing NICD has been 
reported to inhibit adipogenic differentiation, while siRNA medicated knock down 
of Hes-1 also decreased adipogenesis in 3T3-L1 pre-adipocytes (151).  These 
apparently conflicting results suggest that effects of Notch signaling on MSC 
differentiation in vitro are either cell type dependent or the temporal expression 
and magnitude of activation is important for the specific effect of notch on MSC 
differentiation.   
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More recent studies have established the importance of Notch signaling in 
regulating MSC lineage cells in vivo.  Over-expressing NICD in osteoblasts using 
a 2.3kb type I collagen promoter was shown to increase immature, woven 
trabecular and cortical bone.  The increase in bone mass was due to an increase 
in osteoblast number caused by an increase in proliferation.   The osteoblasts 
present were less mature than wild-type controls as demonstrated by decreased 
expression of late differentiation markers (137).  This gain of function model 
demonstrates that notch signaling is sufficient to promote osteoblast proliferation 
but it inhibits terminal differentiation or proper function of osteoblasts.  In another 
study, over-expressing NICD from a different type I collagen promoter (Col3.6) 
resulted in high levels of embryonic lethality.  In contrast to the Col2.3-NICD mice, 
the few mice that survived displayed an osteopenic phenotype with decreased 
trabecular bone mass (136).  Taken together, these two studies again suggest 
that temporal activation of Notch signaling may be important for its effect on 
osteogenic differentiation.  
Hilton et al crossed Prx-1Cre mice with Notch1-/f /Notch2fl/fl  or Psen1fl/fl/ 
Psen2 -/- mice to inactivate notch signaling in early mesenchymal progenitors by 
deleting Notch 1 and 2 or presenilins 1 and 2 (175).  Mice in which notch 
signaling was inactivated in these early mesenchymal progenitors displayed a 
decrease in CFU-F numbers and massive accumulation of trabecular bone at 8 
weeks of age.   Interestingly, as these mice aged, there was significant decrease 
in bone mass such that at 24 weeks of age, they had ~10% of the bone mass as 
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wild type controls.  The authors of that study concluded that notch signaling 
maintains osteoprogenitor numbers by preventing osteogenic differentiation.   
 Molecular mechanisms through which notch signaling influences 
osteogenic differentiation have also been examined.  Engin et al demonstrated 
direct interaction between NICD and the osteoblast transcription factor Runx-2, 
while Hilton et al showed that both Hey-1 and Hey-2 physically interact with 
Runx-2 (137, 175).  Both studies further showed these physical interactions with 
Runx-2 resulted in a decrease in Runx-2 transcriptional activity at a well-
characterized osteocalcin promoter.  Another proposed mechanism for notch 
mediated inhibition of osteogenesis is that Notch signaling, acting through Hes-1, 
blocks osteogenic differentiation by blocking wnt signal activation (139-141).  
Considered together, these results suggest that Notch may act through both 
canonical (through CSL and Hes and Hey transcription) and non canonical (direct 
interaction between NICD and Runx-2) mechanisms to regulate MSC 
differentiation.   
 Although these previous studies firmly establish a role for notch signaling 
in regulating MSC fate, several questions remain.  First, although the role of 
notch signaling on osteogenic and adipogenic differentiation was investigated in 
various cell lines, no study to our knowledge has examine the effects of 
activating notch on differentiation and proliferation of primary MSC.  Second, 
whether any or all of the effects of notch signaling in vivo are mediated through 
CSL-mediated signaling has not been shown.  Finally, it is not clear whether the 
increase in bone mass seen at a young age in Prx-1 mediated Notch inactivation 
 
 57 
models is due to embryonic developmental defects that persist post-natal or 
whether it is something that truly arises from an increase in osteogenic 
differentiation.  
 Herein, we address these issues by examining the role of notch signaling 
on primary murine MSC proliferation and differentiation. Additionally, we examine 
the impact of specifically inactivating canonical notch signaling using a Cre-loxP 
regulated dominant negative form of MAML (dnMAML).    
 
Materials and Methods: 
Mice:  Prx-1Cre, Mx-1Cre, Col2.3Cre and dnMAMLfl/fl mice have been described 
(121, 176-178).  All procedures were approved by the institutional animal care 
and use committee.  Cre transgenic mice were crossed with dnMAMLfl/fl and 
either F1 or F2 generation mice were euthanized at indicated ages and hind-
limbs harvested for either microCT analysis or cell harvest.  To induce cre 
recombinase expression in Mx1Cre/dnMAML mice, 500μg 
Polyinosinic:Polycytidylic acid (P(I):(C))(Sigma, St. Louis, MO) was administered  
i.p. every 2 days for 20 days starting at eight week of age as previously 
described (127).  
 
Cell culture and treatment:   Whole bone marrow from femora and tibiae of 
C57/BL6 mice was cultured in MSC media (alpha-Minimum Eagle’s medium 
supplemented with 10% fetal bovine serum, 2 mM L-glutamine, 25μg/mL sodium 
ascorbate, and 100U/mL penicillin and 100μg/mL streptomycin) for 8 to 10 days.  
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When cultures reached 80% confluence, cells were trypsinized, then plated onto 
12-well or 24-well tissue culture plates at a density of 1X105 or 0.5X105 cells per 
well, respectively.  To activate Notch signaling using immobilized Jagged-1 tissue 
culture plates were pre-coated with 10μg/mL anti-Fc IgG antibody (Jackson 
Immunoresearch) for 1 hour then treated with the indicated concentration of 
recombinant rat Jagged-1/human Fc-IgG chimeric protein for 2 hours (R&D 
Systems).   Wells that were coated with the anti-Fc antibody but not treated with 
the Jagged-1 protein served as negative controls.  
 
CFU-F assay:  Single cell suspensions of whole bone marrow were counted and 
3X106 cells were plated onto 60cm tissue culture plates in MSC media.  Half the 
media was replaced four days post plating then every 3 days for 13 days.  CFU-F 
plates were then fixed and stained for alkaline phosphatase activity as previously 
described (103) and total, as well as alkaline phosphatase positive colonies were 
counted under a dissecting microscope. 
  
Induction of osteogenic and adipogenic differentiation:  For osteogenic 
differentiation, cells were treated and maintained in osteogenic media containing 
5mM β-glycerol phosphate and 100μM ascorbate.  For adipogenic induction, 
cells were grown until they reached confluence and induced with MDIT (57μM 
isobutyl-methylxanthine, 1μM dexamethasone, and 1μg/mL insulin, and 5μg/mL 
troglitazone) for three days then maintained in 1μg/mL insulin for the remainder 
of the differentiation experiments.  Extent of osteogenic and adipogenic 
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differentiation was evaluated by Alizarin Red-S or Oil Red-O staining, 
respectively. In some experiments 1μM of gamma secretase inhibitor (GSI), L-
685,458 (Sigma) was added daily to cells to bock notch signaling.   
 
RNA extraction and quantitative RT- PCR:  RNA was extracted using RNeasy 
RNA extraction kit (Qiagen) according to the manufacturer’s instruction and 1μg 
of total RNA was reverse transcribed in a 20μL reaction. 1μL of the cDNA 
generated was used for quantitative real-time PCR reaction using SybrGreen for 
detection on ABI 7500 Fast real-time PCR machine.  Relative changes in gene 
expression were determined by the 2ΔΔC(T) method using β-actin as an 
endogenous control.  
 
Statistical Analysis:  Student’s t-tests were used to compare means between 
control treated and Jagged-1 treated groups.  Two-way ANOVA analysis was 
used to determine whether micro-CT parameters were significantly different 




Jagged-1 decreases matrix mineralization and osteocalcin expression.   
Several investigators have examined the role of notch signaling on osteogenic 
and adipogenic differentiation in vitro and have reported conflicting results (141-
144).  Significant limitations of these previous studies include the use of 
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immortalized cell-lines which may not accurately reflect the behavior of primary 
cells and the reliance on over-expressed NICD to activate notch signaling which 
may result in super-physiological levels of notch activation.  To overcome these 
limitations, we evaluated the effects of ligand mediated activation of notch 
signaling on MSC differentiation. 
 Primary MSC from wild type C57/BL6 mice were plated onto wells coated 
with either Fc-control or Jagged-1 and were induced to undergo osteogenesis 4 
days later in the presence or absence of a γ-secretase inhibitor (GSI) (Figure 3.1 
A).  Alizarin Red-S staining at 4 and 8 days post induction revealed decreased 
mineralized matrix formation in cells plated on Jagged-1 relative to cells plated 
on Fc-control.  Although GSI treatment by itself did not have an apparent effect 
on mineralized matrix formation, it was able to rescue the decrease in 
mineralization caused by Jagged-1 treatment.  To determine whether Jagged-1 
affects osteogenic differentiation, expression of the late osteogenic differentiation 
marker osteocalcin was evaluated in MSC plated on either Fc control or Jagged-
1 and induced to undergo osteogenesis for 8 days.  Jagged-1 treatment reduced 
osteocalcin expression to 26% of cells treated with the Fc-control (Figure 3.1 B).  
To determine whether Jagged-1 causes decreased mineralization by decreasing 
cell numbers, equal numbers of MSC were plated onto wells coated with either 
Jagged-1 or Fc-control then were trypsinized and counted using a 
hemocytometer.   Plating cells on Jagged-1 resulted in a 59% increase in cell 
number relative to Fc-control (Figure 3.1 C).  Taken together, these results 
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suggest that Jagged-1 reduces osteogenic differentiation and increases cell 
number.  
 
Osteogenic induction decreases Hey-1 and Hey-L expression.  
Members of the Hes and Hey family of transcription factors are believed to 
be major effectors of notch signaling.   To determine if Jagged-1 treatment or 
osteogenic induction alter expression of these notch target genes, MSC were 
plated onto wells coated with either Jagged-1 or Fc-control and were induced to 
undergo osteogenic differentiation 4 days later.  RNA was harvested at 4 and 8 
days post osteogenic induction and expression of the six Hes and Hey family 
members believed to be notch responsive (Hes-1, Hes-5, Hes-7, Hey-1, Hey-2 
and Hey-L) was measured by qPCR.   No appreciable change in expression of 
Hes-1, Hes-5 or Hes-7 was detected with either Jagged-1 treatment or 
osteogenic induction.  Hey-1, Hey-2 and Hey-L expression increased greater 
than 10 fold in cells plated on Jagged-1 relative to Fc controls in both osteogenic 
induced and control treated cells at day 4 and remained at that increased level at 
day 8 (Figure 3.2, data not shown).  Interestingly, osteogenic induction reduced 
Hey-1 expression to 56% and 27% of un-induced controls at 4 and 8 days post 
osteogenic induction, respectively.   Similarly, osteogenic induction decreased 
Hey-L levels to 72% and 28% of un-induced controls 4 and 8 post induction, 
respectively (Figure 3.2).  There was no appreciable change in Hey-2 expression 
with osteogenic induction (data not shown).  Taken together, these results 
suggest that Hey-1, Hey-2  and Hey-L are responsive to notch signaling 
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activation by Jagged-1 in MSC and Hey-1 and Hey-L may be important 
mediators of notch signaling in MSC during osteoblast differentiation.   
 
Jagged-1 increases lipid accumulation by increasing cell number.   
To examine the role of activating notch signaling on adipogenic 
differentiation, primary MSC were grown on either Jagged-1 or Fc-control coated 
wells for four days.  Cells were then induced to undergo adipogenic 
differentiation for 10 days in the presence or absence of GSI and were stained 
with Oil Red-O and DAPI (Figure 3.3).  Absorbance measurements on Oil Red-O 
extracted from cells induced to undergo adipogenesis showed a 2.5 fold increase 
in Oil Red-O incorporation in cells plated on Jagged-1 relative to cells plated on 
Fc-control.   Interestingly, treating cells with GSI starting at the time of adipogenic 
induction also resulted in a significant increase in Oil-Red-O incorporation 
relative to non-GSI treated cells plated on either Fc-control (2.1 fold increase) or 
Jagged-1 (1.9 fold increase).   The greatest increase in Oil Red-O incorporation 
was observed in cells grown on Jagged-1 and treated with GSI at the time of 
adipogenic induction (Figure 3.3 A).  Next we asked whether the increase in 
adipogenic differentiation observed with either Jag-1 or GSI treatment is related 
to cell number.  Counting the number of DAPI staining nuclei in each well 
revealed a 2 fold increase in the number of DAPI staining nuclei in Jagged-1 
treated cells relive to Fc treated cells under control, adipogenic and adipogenic + 
GSI induction conditions. Normalizing Oil Red-O absorbance measurements to 
cell number resulted in no significant difference in Oil Red-O incorporation 
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between Jagged-1 and Fc-control treated cells induced with either adipogenic 
media or adipogenic media containing GSI.  Oil Red-O incorporation remained 
significantly higher in GSI treated cells plated on either Fc-control (2.6 fold 
increase) or Jagged-1 (1.9 fold increase) after normalizing to cell number.  
Therefore, Jagged-1 increases lipid accumulation in MSC cultures by increasing 
cell number and GSI increases lipid accumulation independent of cell number.    
 
Canonical Notch regulates bone mass in vivo.  
Previous studies have shown that both NICD and the down-stream target of 
canonical notch signaling, Hey-1, can physically interact with Runx-2 and block 
its’ transcriptional activity (137, 175).  Studies that examined the role of notch 
signaling in vivo have relied on either over-expressing NICD or deleting notch 
receptors or presenilins.   All of these approaches could potentially influence both 
canonical (CSL-mediated) and non-canonical notch signaling pathways such as 
NICD interaction with Runx-2.  To determine the effects of specifically blocking 
canonical notch signaling in bone formation in vivo, we used mice that carry a  
transgene for a dominant negative form of Mastermind-like-1 fused with GFP 
(dnMAMLfl/fl).   The dnMAML transgene is only expressed under Cre-mediated 
deletion of an upstream stop codon (178).  We crossed dnMAMLfl/fl mice with 
Col2.3Cre and Prx-1Cre mice to drive dnMAML expression in osteoblasts and 
early mesenchymal progenitor cells, respectively, and with Mx-1Cre mice to 
temporally regulate global expression of dnMAML by administering P(I):P(C) 
(Figure 3.5) (119, 172-174).   
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 To activate dnMAML expression in osteoblast lineage cells, Col2.3Cre 
mice were first crossed with dnMAMLfl/fl  mice and the resulting F1 generation 
offspring Col2.3Cre+/dnMAMLfl/+ mice were crossed again with dnMAMLfl/fl mice.  
Out of greater than 10 breeding pairs set up between Col2.3Cre+/dnMAMLfl/+  X  
dnMAMLfl/fl  mice, there were no Col2.3+/ dnMAMLfl/fl pups that survived until 
weaning but both F1 and F2 generation Col2.3Cre+/dnMAMLfl/-  were viable and 
survived to at least 6 months of age.  Tails of less than 5% of F1 generation 
Col2.3Cre+/dnMAMLfl/- mice appeared crooked at the time of weaning (6 weeks 
of age) but otherwise the mice appeared normal.  In contrast, all F2 generation 
Col2.3Cre+/dnMAMLfl/-  mice developed a “crooked-tail” phenotype and in 
addition appeared to be smaller than their Col2.3Cre-/dnMAMLfl/- littermates and 
had patchy grey hair on the dorsal surface of their body  (Figure 3.4 A).   
Radiographic examination revealed that affected F2 generation 
Col2.3Cre+/dnMAMLfl/- mice had vertebral malformations similar to what is 
described in Alagille Syndrome patients, including hemi-vertebrae (butterfly-spine) 
(Figure 3.4 B).   The severity of vertebral malformation as well as the vertebral 
segment affected (thoracic vs. lumbar vertebrae) varied from mouse to mouse.  
The hind-limbs of more severely affected mice were paralyzed and they could 
only ambulate using their fore-limbs.  Because the severe vertebral 
malformations and paralysis of hind-limbs of  F2 generation Col2.3Cre+/dnMAML 
fl/- mice would make interpretation of the effects of dnMAML on bone formation 
difficult, only F1 generation mice, which rarely displayed any vertebral 
malformation, were analyzed further.  Micro-CT analysis of femora from eight 
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week old mice revealed no significant difference in bone volume fraction (bone 
volume/total volume (BV/TV)), trabecular connective density, trabecular number 
or trabecular thickness between F1 generation Col2.3Cre+/dnMAML fl/-  mice and 
age matched Col2.3Cre-/dnMAML fl/- littermate controls (Table 3.1).  
To determine the effects of dnMAML expression on osteogenic 
differentiation, MSC from eight week old Col2.3Cre-/dnMAML fl/- and 
Col2.3Cre+/dnMAML fl/- controls were induced to undergo osteogenic 
differentiation in the presence or absence of GSI.  Alizarin Red-S staining of 
plates at 10 days post osteogenic induction revealed increased mineralized 
matrix formation in MSC harvested from Col2.3Cre+/dnMAMLfl/- mice relative to 
MSC harvested from Col2.3Cre-/dnMAMLfl/- controls.  GSI treatment started at 
the time of osteogenic induction had no apparent effect on mineralized matrix 
formation in either Col2.3Cre-/dnMAMLfl/- or Col2.3Cre+/dnMAML fl/-  MSC.  
dnMAMLfl/fl mice were also crossed with Prx-1Cre mice to activate 
expression of the dnMAML in early mesenchymal progenitors.  Gross 
observation and radiographic examination of 8 week and 6 month old  F1 and  F2 
generation Prx-1Cre+/dnMAMLfl/- and Prx-1Cre-/dnMAMLfl/-  mice did not reveal 
any apparent skeletal malformations, differences in whole body size or 
abnormalities of the skin.  Micro-CT analysis of trabecular parameters of bone 
mass in femurs from 8 week old mice  showed an 18% decrease in bone volume 
fraction (BV/TV) in Prx-1 Cre+/dnMAML fl/- when compared  to  Prx-1Cre-
/dnMAMLfl/- littermate controls.  However, trabecular connectivity density, 
trabecular number, trabecular thickness or trabecular spacing were not 
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significantly different between 8 week old Prx-1 Cre+/dnMAML fl/- mice and Prx-
1Cre-/dnMAMLfl/-  littermate controls (Table 3.2 A).  Trabecular bone mass 
parameters of femora from 6 month and 14.5 month old mice were also analyzed 
but revealed no significant differences in BV/TV, trabecular connective density, 
trabecular number, trabecular thickness or trabecular spacing between Prx-1 
Cre+/dnMAML fl/- mice and  Prx-1 Cre-/dnMAMLfl/- littermate controls (Table 3.2 
B,C).    
In order to study the effects of inducing dnMAML expression globally on 
bone formation, dnMAMLfl/fl  mice were crossed with Mx1Cre mice in which Cre 
expression can be induced globally  by administering P(I:C) to mice.  First, the 
efficacy of a P(I:C) treatment regimen (shown to be effective in inducing 
recombination and dnMAML expression in >95% of HSC lineage cells) in 
inducing dnMAML expression in mesenchymal lineage cells was examined.  8 
week old Mx1Cre-/dnMAMLfl//fl and Mx1Cre+/dnMAMLfl//fl mice were treated with 
P(I:C) then euthanized at 6 months of age and  adherent population of cells were 
expanded in vitro and GFP expression was analyzed using fluorescence 
microscopy and FACS analysis (Figure 3.7).   Using microscopy, GFP 
expression was detected in the majority of the adherent cells with fibroblastic 
morphology (Figure 3.7 A). Similarly, on average greater than 85% of the 
adherent cells were found to express GFP using FACS analysis (Figure  3.7 B,C).  
Trabecular bone mass parameters in femurs of 6 month old Mx1Cre+/dnMAMLfl//fl 
mice and Mx1Cre-/dnMAMLfl// littermate controls treated with P(I:C) starting at 8 
weeks of age were then analyzed using micro-CT.  Bone volume fraction (BV/TV), 
 
 67 
trabecular number and thickness were reduced by 39.8%, 49.0%, 8.3%, 
respectively, and trabecular spacing was increased by 11.3% in 
Mx1Cre+/dnMAMLfl//fl mice relative to Mx1Cre-/dnMAMLfl// littermate controls 
(Table 3.3).  To determine whether the decrease in trabecular bone mass in 
Mx1Cre+/dnMAM fl/fl mice was due to a decrease in osteoprogenitors, CFU-F 
assays were performed on bone marrow cells harvested from 
Mx1Cre+/dnMAMLfl//fl mice and Mx1Cre-/dnMAMLfl// littermate controls mice.  No 
significant difference in either the total number or the percentage of alkaline 
phosphatase positive colonies was detected between P(I:C) treated 6 month old 
Mx1Cre+/dnMAMLfl//fl mice and Mx1Cre-/dnMAMLfl// littermate control (Figure 3.8).    
 
Discussion  
 In this study, we investigated the role of activating notch signaling using 
immobilized Jagged-1 on primary MSC differentiation and found that Jagged-1 
decreases mineralized matrix formation and gene expression of the late 
osteogenic differentiation marker, osteocalcin.  Previous studies that investigated 
the role of activating notch signaling on osteogenic differentiation have reported 
conflicting results.  Possible reasons for these conflicting results are differences 
in cells types used and the extent and duration of notch activation.  Considered 
together, results from these previous studies indicate that stable activation of 
notch signaling in cells with multi-lineage differentiation potential inhibits 
osteogenic differentiation while transient activation in committed pre-osteoblasts 
promotes osteogenic differentiation (138, 142-144, 146).   
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Our experimental approach of using immobilized Jagged-1 to activate 
notch signaling in primary MSC most resembles the stable NICD over-expression 
models because expression of notch target genes remain elevated for the 
duration of our differentiation experiments and resulted in a similar outcome. 
Consistent with previous reports that showed GSI treatment decreases human 
MSC proliferation, we found that plating cells on Jagged-1 results in an increase 
in cell number (179).  It is therefore possible that the increase in matrix 
mineralization that is seen with transient notch activation models is due to an 
increase in cell number.  In future experiments it would be interesting to 
determine the length of time that immobilized Jagged-1 can continue to activate 
notch signaling and whether an increase in matrix mineralization can be 
observed once Jagged-1 is no longer active.   
We also examined changes in expression of Hes-1, Hes-5, Hes-7, Hey-1, 
Hey-2 and Hey-L in primary MSC and  found that only Hey-1, Hey-2 and Hey-L 
were responsive to Jagged-1 treatment and Hey-1 and Hey-L  levels decrease 
with osteogenic differentiation.   Our results are consistent with a previous report 
that showed of the six notch targets examined, expression of only Hey-1, Hey-2 
and Hey-L mRNA was detectable in mRNA harvested from mouse tibiae.  
Interestingly, Hey-1 and Hey-L but not Hey-2 mRNA was shown to be decreased 
in tibias from mice in which γ-secretase activity was deleted using the Prx1 
promoter, further suggesting that Hey-1 and Hey-L may be key mediators of 
notch signaling effects on MSC (175).  Our results which show decreased Hey-1 
and Hey-L expression during osteogenic differentiation further suggest that notch 
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signaling is inhibited during osteogenic differentiation and provides a possible 
explanation for why GSI treatment starting at the time of osteoblast induction has 
a minimal effect on differentiation, but is able to rescue Jagged-1 mediated 
decrease in matrix mineralization.   
We also examined the role of Jagged-1 mediated notch activation on 
adipogenic differentiation of primary MSC and found that it increases lipid 
accumulation as determined by Oil-Red-O and cell number and that the effect on 
lipid accumulation appears to be primarily due to an increased cell number.  GSI 
treatment starting at the time of adipogenic induction also increases lipid 
accumulation but its’ mechanism appears to be independent of any effect on cell 
number.  Previous studies on the role of notch signaling in adipogenesis have 
reported conflicting results. For instance, over-expression of Hes-1 inhibits 
adipogenesis and siRNA mediated knock down of Hes-1 also decreases 
adipogenesis in 3T3L1 cells suggesting that while some Hes-1 expression is 
required, too much expression may be inhibitory for adipogenesis (151, 180). Our 
results that show GSI treatment increases lipid accumulation contradict a 
previous report by Hilton et al that showed a decrease in lipid accumulation in 
MSC isolated from mice in which notch signaling was inactivated using Prx1 
promoter (175).  The same study also showed that MSC from these same mice 
undergo accelerated osteogenic differentiation, therefore it is possible that the 
decrease in lipid accumulation is due to increased osteogenic commitment in 
vivo and not a direct effect of notch inactivation on adipogenic differentiation in 
vitro.   
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We also examined the effects of over-expressing dnMAML in MSC lineage 
cells on trabecular bone mass.  Unexpectedly, we found that driving dnMAML 
expression using Col2.3Cre mice results in vertebral malformations similar to that 
is seen in Alagille Syndrome.  Alagille syndrome is caused by mutations in 
Jagged-1 and the vertebral malformations seen in these patients are thought to 
arise from disruption of cyclic activation of notch signaling during somitogenesis.  
Our findings, therefore, suggest that the Col2.3 promoter drives Cre expression 
in somites but more studies are required to determine whether dnMAML 
expression is induced during somitogenesis in Col2.3Cre+/dnMAMLfl/- mice.  
Our finding that Prx1Cre driven expression of dnMAML results in no 
significant change in trabecular bone mass at either 8 weeks, 6 months or 14.5 
months of age contradict Hilton et al’s study that showed massive increase in 
trabecular bone at 8 weeks of age and severe osteopenia seen at 6 months of 
age when notch receptors were inactivated using the Prx1Cre mice.   There are a 
number of possible explanations for the disparity in phenotype between this 
previous report and our results.  First, there could be differences in the extent of 
notch inhibition between the previous report in which Notch-1 and Notch-2 or 
presenillin-1 and presenillin-2 were deleted and our dnMAML expression model.  
Second, it is possible that inactivating canonical notch signaling alone, as our 
dnMAML approach presumably does, is not sufficient to influence MSC function 
and that decreasing NICD levels are also required for the effects of notch on 
MSC function to become apparent.  This explanation is supported by a report by 
Engin et al that showed physical and functional interactions between NICD and 
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Runx-2.  Future studies should examine the extent of notch inhibition achieved 
using the dnMAML approach relative to what is achieved by receptor deletion 
models.  Whether specifically inhibiting canonical notch signaling in 
mesenchymal progenitors is dispensable for MSC function, as our results 
suggest, should also be confirmed using other mouse models in which CSL 
mediated notch signaling can be selectively inactivated.    
Our results that show P(I:C) induced dnMAML expression decreases 
trabecular bone mass while Prx1Cre induced expression has little effect suggests 
that dnMAML, when driven from Mx1Cre promoter, may have a more dominant 
effect on osteoclast lineage cells than in osteoblast lineage cells.  This notion is 
supported by the our observation that CFU-F numbers were not significantly 
decreased in P(I:C) induced Mx1Cre+/dnMAML fl/fl mice and previous reports that 
have shown that inactivating notch signaling increases bone resorption directly 
by promoting osteoclast differentiation from osteoclast progenitors and indirectly 
by increasing RANK-L expression in osteoblasts (137, 181).  Future studies 
should address whether the decrease in trabecular bone mass in 
Mx1Cre+/dnMAML fl/fl mice is due to a decrease in bone formation and/or an 
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Figure 3.1 Immobilized Jagged-1 decreases matrix mineralization and 
osteocalcin expression and increases cell number.   MSC were cultured on 
plates coated with either Fc-control (Fc) or 5μg/mL of Jagged-1 (Jag-1) for 4 
days and were induced to undergo osteogenic differentiation in the presence or 
absence of a γ-secretase inhibitor (+GSI).  A) Plates were stained with Alizarin 
Red-S at 4 and 8 days post induction and representative images from two 
independent experiments done with two independent MSC harvests is shown. B) 
MSC were induced to undergo osteogenic differentiation on either Fc-control or 
5μg/mL of Jagged-1 for 8 days and RNA was harvested and change in 
osteocalcin expression on Jag-1 relative to Fc-controls was determined by qPCR.   
Graphs represent mean + S.D of two independent experiments done on two 
independent MSC harvests each done in duplicate.  C) MSC were plated on 
either Fc-control or 5μg/mL of Jagged-1 in triplicates then were trypsinized and 
counted 4 days later.  Data shown are representative of two independent 
experiments and graphs are mean + S.D. of triplicate samples.  (#= Jag-1 



















































































Figure 3.2   Osteogenic induction decreases Hey-1 and Hey-L expression 
and Jagged-1 treatment increases and maintains it at elevated levels.  MSC 
were plated onto either Fc-control or 5μg/mL Jagged-1 (Jag 1) coated wells and 
were induced to undergo osteogenic differentiation.  RNA was harvested at 4 and 
8 days post osteogenic induction and  expression of Hey-1 and Hey-L was 
analyzed by quantitative-RT PCR.  Graphs represent fold change in expression 
of Hey-1 and Hey-L relative to un-induced control cells plated on Fc-control 
(value of 1).  Graphs are mean + S.D. of two independent experiments from two 
independent cell harvests each done in duplicate.  For each experiment, whole 
bone marrow from 3 mice was pooled to yield MSC.  (#=osteogenic induced 
significantly different from un-induced controls, *=Jag-1 significantly different from 
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 Figure 3.3  
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Figure 3.3  Jagged-1 increases lipid accumulation by increasing cell 
number.   MSC were plated onto either Fc-control (Fc) or 5μg/mL Jagged-1 
(Jag-1) coated wells and induced to undergo adipogenic differentiation 4 days 
later (Adipogenic)  in the presence or absence of γ-secretase inhibitor (GSI) 
(Adipogenic + GSI).  Ten days post induction, cells were stained with Oil Red-O 
and DAPI and 5 representative 10X DAPI fluorescence images were obtained.  A) 
Scanned image of a representative Oil Red-O stained plate is shown   B) Oil 
Red-O was extracted and quantified by measuring absorbance at 540nm and 
graphed as fold change over cells induced to undergo adipogenesis on Fc-
control.  C) the total number of DAPI staining nuclei in 5 images obtained from 
each well was averaged and used as an estimate of the total number of cells in 
each well and graphed as fold change over un-induced control cells plated on Fc 
control.  D)  Oil Red-O absorbance readings were normalized to cell number 
(number of DAPI staining nuclei) and graphed as fold change over cells induced 
to undergo adipogenesis on Fc-control.  Data shown are mean + S.D. of two 
independent experiments each done in duplicate on two independent MSC 
harvests. ( #=Jag-1 significantly different from Fc control,  *=GSI treated 







































































































Figure 3.4 dnMAML construct and experimental approach.  The dnMAML 
mice carry a PGK-Neo-tpA cassette with a stop codon flanked by loxP sites 
(floxed) upstream of dnMAML-GFP fusion protein knocked into the ROSA locus.  
Crossing them with mice that express cre recombinase from a Col2.3, Prx1, and 
Mx1 promoter excises out the PGK-Neo-tpA cassette and allows transcription of 
dnMAML-GFP from the ROSA promoter in osteoblasts, mesenchymal 
progenitors, or in a PolyI:PolyC  inducible manner, respectively.  
stop
dnMAML GFP
Col I 2.3-Cre Prx1-Cre Mx1-Cre



























Figure 3.5  Col2.3dnMAML mice develop vertebral malformations similar to  
Alagille Syndrome patients.  A) Picture of 6 month old F2 generation mice 
illustrates the characteristic appearance of Col2.3+/dnMAMLfl/-   and Col2.3-
/dnMAMLfl/- mice.  Col2.3+/dnMAMLfl/- mice are smaller and have  a characteristic 
“crooked tail”.   The hind-limbs of more severely affected mice are paralyzed but 
they can move around their cage using their fore-limbs.  B) Radiographic image 
of a Col2.3-/dnMAMLfl/- and Col2.3+/dnMAMLfl/-  mice demonstrates vertebral 
malformation in Col2.3+/dnMAMLfl/-  mice similar to what is seen in Alagille 
Syndrome patients including characteristic hemi-vertebrae (butterfly-spine) 
































Figure 3.6 MSC from Co2.3Cre+/dnMAMLfl/- mice show increased 
mineralized matrix formation.   MSC isolated from hind-limbs of eight week old 
F1 generation Co2.3Cre+/dnMAMLfl/- mice and Co2.3Cre+/dnMAMLfl/- littermate 
controls were induced to undergo osteogenesis in the presence or absence of 
GSI for 8 days and were stained with Alizarin-Red-S.  Representative wells from 
two independent experiments performed on two independent MSC harvests are 
depicted.  For each harvest, bone marrow from three Co2.3Cre+/dnMAMLfl/- and 













Table 3.1  
 
Trabecular microCT parameter Col2.3Cre-/dnMAMLfl/- Col2.3Cre+/dnMAMLfl/- 
BV/TV  0.0968 (0.0141)  0.0977 (0.0178) 
Connectivity density 85.058 (8.903) 74.728 (11.262) 
Trabecular number 3.112 (0.166)  2.973 (0.210)  
Trabecular thickness (mm) 0.0548 (0.00337)  0.0590 (0.00426) 
Trabecular spacing (mm) 0.321 (0.0174)  0.334 0.0221 
     (Cre negative, n=5; Cre positive, n=4),  Mean (SEM) 
 
 
Table 3.1  Femora from 8 week old F1 generation Co2.3Cre+/dnMAMLfl/- 
mice have normal trabecular bone mass and geometry.  Femora from gender 
matched 8 week old Col2.3Cre+/dnMAMLfl/- mice and Col2.3Cre-/dnMAMLfl/- 
littermate controls were harvested and trabecular bone mass parameters were 
determined using micro-CT.  Only F1 generation mice were analyzed because 
F2 generation Col2.3+Cre/dnMAMLfl/- mice develop vertebral malformations that 
affected use of their hind-limbs for locomotion.  There were no significant 
differences in any of the trabecular bone mass parameters between 








   8 weeks old 
Trabecular microCT parameter Prx1Cre-/dnMAMLfl/- Prx1Cre+/dnMAMLfl/- 
BV/TV  0.242 (0.0157)  0.199 (0.00864)* 
Connectivity density 503.076 (27.913)   460.482 (15.329) 
Trabecular number 6.064 (0.330)  5.437 (0.181)  
Trabecular thickness (mm) 0.0511 (0.00210) 0.0481 (0.00115) 
Trabecular spacing (mm) 0.175 (0.00509)  0.185 (0.00280) 




   6 months old 
Trabecular microCT parameter Prx1Cre-/dnMAMLfl/- Prx1Cre+/dnMAMLfl/- 
BV/TV  0.121 (0.0167)  0.127 (0.0125)  
Connectivity density 86.759 (15.743)  110.185 (10.765) 
Trabecular number 3.199 (0.192)  3.279 (0.144)  
Trabecular thickness (mm) 0.0554 (0.00210)  0.0529 (0.00157)  
Trabecular spacing (mm) 0.359 (0.0330)  0.357 (0.0247)  




   14.5 months old 
Trabecular microCT parameter Prx1Cre-/dnMAMLfl/- Prx1Cre+/dnMAMLfl/- 
BV/TV  0.0967 (0.0294)  0.0915 (0.0285)  
Connectivity density 79.710 (38.251) 97.894 (26.608) 
Trabecular number 2.402 (0.195)  2.588 (0.189)  
Trabecular thickness (mm) 0.0611 (0.00406)  0.0497 (0.00393)  
Trabecular spacing (mm) 0.528 (0.0516) 0.437 (0.0499)  
    (Cre negative, n=4; Cre positive, n=5), Mean (SEM) 
 
 
Table 3.2  Femora from 8 week old Prx1Cre+/dnMAMLfl/- mice have a 
decrease in trabecular bone volume fraction.  Femora from gender matched 8 
week old (A), 6 month old (B) and 14.5 month old (C) Prx1Cre+/dnMAMLfl/- mice 
and Prx1Cre-/dnMAMLfl/- littermate controls were harvested and trabecular bone 
mass parameters were determined using micro-CT.  8 week old 
Prx1Cre+/dnMAMLfl/-mice have significantly decreased bone volume fraction 
(BV/TV) when compared to Prx1Cre-/dnMAMLfl/- littermate controls.  There were 
no significant differences between Prx1Cre+/dnMAMLfl/-  and Prx1Cre-/dnMAMLfl/- 
mice in any of  the trabecular parameters analyzed at either 6 month or 14.5 
month of age.  
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Figure 3.8    P(I:C) treatment induces dnMAML expression in MSC.  8 week 
old Mx1Cre-/dnMAMLfl/fl and Mx1Cre+/dnMAMLfl/fl mice were treated with a 
regimen of P(I:C) injections then were euthanized at 6 months of age and extent 
of dnMAML expression in MSC was determined by monitoring GFP expression.  
A) First passage MSC were stained with TRITC conjugated phalloidin and DAPI 
to stain actin cytoskeleton and nuclei, respectively.  Most Mx1Cre+/dnMAMLfl/fl 
cells with fibroblastic morphology also express GFP indicating that dnMAML 
expression has been activated.  B) A representative FACS analysis showing the 
shift in GFP fluorescence intensity in first passage MSC from an Mx1Cre-
/dnMAMLfl/fl mouse relative to MSC from an Mx1Cre-/dnMAMLfl/fl control.  C) The 
percentage of GFP positive cells in first passage MSC from Mx1Cre-/dnMAMLfl/fl 












































Trabecular microCT parameter Mx1Cre-/dnMAMLfl/fl  Mx1Cre+/dnMAMLfl/fl 
BV/TV  0.0841 (0.00418)  0.0506 (0.00441)* 
Connectivity density 101.715 (7.338)  52.242 (7.735)* 
Trabecular number 3.612 (0.0902)  3.279 (0.0950)* 
Trabecular thickness (mm) 0.0426 (0.00121)  0.0370 (0.00128)* 
Trabecular spacing (mm) 0.283 (0.00878) 0.315 (0.00925)* 
     (Cre negative, n=6; Cre positive, n=5), Mean (SEM),  *, p<0.05 
 
 
Table 3.3  P(I:C) induced expression of dnMAML decreases trabecular bone 
mass.  8 week old Mx1Cre-/dnMAMLfl/fl and Mx1Cre+/dnMAMLfl/fl mice were 
treated with P(I:C) injections then were euthanized at 6 months of age. Femurs 
were collected and trabecular bone mass parameters were analyzed using 
micro-CT.  P(I:C) treated Mx1Cre+/dnMAMLfl/fl mice had a significant decrease in 
BV/TV, trabecular connective density and number and an increase in trabecular 





























Figure 3.9 P(I:C) induced expression of dnMAML does not alter CFU-F 
numbers.  8 week old Mx1Cre-/dnMAMLfl/fl and Mx1Cre+/dnMAMLfl/fl mice were 
treated with P(I:C) then were euthanized at 6 months of age and bone marrow 
was harvested from hind-limbs and was plated for CFU-F assay.  Cells were 
fixed and stained for alkaline phosphatase (AP) activity 13 days post plating and 
total and AP positive colonies were counted and percentage of AP positive 
colonies (%AP) was determined.  Total number of CFU-F and percentage of AP 
positive colonies from five Mx1Cre-/dnMAMLfl/fl and five Mx1Cre+/dnMAMLfl/fl 
mice were averaged and graphed as mean + SEM.  There were no statistically 
significant differences in either total number of CFU-F or percentage of AP 
positive colonies between P(I:C) treated Mx1Cre-/dnMAMLfl/fl and 

































THROMBOSPONDIN-2 MODULATION OF NOTCH SIGNALING  
 
Introduction 
Bone marrow derived mesenchymal stem cells (MSC) are precursors that 
give rise to osteoblasts, adipocytes, and chondrocytes.   MSC numbers are 
known to decrease with age and this decrease has been proposed as a possible 
explanation for age-associated osteoporosis (166, 167).  In addition to a 
decrease in MSC number, an increase in bone marrow adipocytes is observed 
with ageing and a switch from osteogenic to adipogenic fate is also thought to 
contribute to the pathogenesis of osteoporosis (55, 57).  A better understanding 
of molecular mechanisms that maintain the MSC pool as well as those that are 
involved in osteogenic and adipogenic fate are therefore important for designing 
novel treatment strategies for age-associated osteoporosis.   
Thrombospondn-2 (TSP2) is an extracellular matrix (ECM) protein that is 
highly expressed by MSC and belongs to a group of proteins often referred to as 
matricellular proteins.  Matricellular proteins interact with cells as well as other 
ECM proteins, but have minimal structural role.   Extensive study of TSP2 
deficient mice has revealed that TSP2 functions in a variety of physiological and 
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patho-physiological processes such as angiogenesis, skin wound healing, 
foreign body reaction and fracture healing (87-89).   TSP2-null mice have an 
increase in cortical bone thickness due to an increase in osteoprogenitor 
numbers.  In vitro, TSP2 inhibits MSC proliferation and promotes osteogenic 
differentiation (100, 101).  The molecular mechanism through which TSP2 
acts to regulate MSC function is however unknown.   
 Structurally, TSP2 is a large glycoprotein that is secreted as a homo-
trimer.  Each TSP2 chain in the trimeric complex is composed of N-terminal, 
pro-collagen, type I repeat, type II repeat, type III repeat and c-terminal 
domains.  Each of these modules has been shown to interact with distinct cell 
surface receptors, ECM proteins, and growth factors to influence a variety of 
cellular processes such as cell adhesion and proliferation.  Recent studies 
have shown that TSP2 can physically interact with Notch receptors and 
ligands and modulate activation of the Notch signaling pathway (103).   
Notch family receptors (Notch 1 to 4) are highly conserved, single pass 
trans-membrane proteins that are activated by cell surface bound ligands of 
the Delta-Serrate like (DSL) family.  In vertebrates there are five DSL family 
members (Delta-like (Dll) -1, -3, -4, and Jagged (Jag)-1,- 2).   Ligand binding 
initiates a series of enzymatic cleavages.  The first cleavage, mediated 
through ADAM family of metalloproteinase, results in shedding of the 
receptor’s ectodomain. A second cleavage by a γ-secretase enzyme complex 
results in the release of Notch intracellular domain (NICD) into the cytoplasm.  
NICD then translocates to the nucleus where it binds the transcription factor 
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CSL (for CBF1, Suppressor of Hairless, or Lag-1).  CSL bound NICD recruits 
the transcriptional co-activator Mastermind Like-1 (MAML) and initiates 
transcription of notch target genes.  The best characterized Notch targets are 
members of the HES and HERP family of beta-helix-loop-helix family of 
transcription factors.  Members of this family that have been shown to be 
notch responsive are Hey-1, Hey-2, Hey-L, Hes-1, Hes-5 and Hes-7 (104-
110).    
Notch signaling has recently been shown to play an important role in 
MSC fate determination.  Over-expressing NICD in osteoblasts in vivo results 
in an increase in their proliferation and inhibits their terminal maturation 
and/or function.  Similarly, inactivating notch signaling in early mesenchymal 
progenitors results in increased osteogenic differentiation and depletion of the 
osteoprogenitor pool.  In chapter III, we have shown that activating notch 
signaling increases primary MSC proliferation and decreases osteogenic 
differentiation.  Therefore, Notch signaling appears to maintain the MSC pool 
by preventing premature osteoblast differentiation and increasing proliferation 
(137, 175).      
 Notch signaling is regulated at multiple levels including ligand and 
receptor expression, post translational modification and transport.  In addition, 
Notch signaling has been reported to be modulated by ECM proteins 
including CCN/Nov and SPARC (153-155). More recently, it was reported that 
TSP2 can physically interact with Notch-3 and Jagged-1.  TSP2 increases 
Hes-1 promoter activity and Notch target gene expression in a lung cancer 
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cell line and in smooth muscle cells, respectively (156).  The similarity in 
function between TSP2 and Notch signaling in regulating MSC proliferation 
and differentiation, as well as the demonstrated interaction between them in 
other cell types lead us to hypothesize that TSP2 will modulate notch 
signaling in MSC. 
 
Materials and Methods: 
Cell culture and treatments:   Whole bone marrow from femurs and tibias of 
TSP2-null and wild-type control mice was collected and cultured in MSC 
media (alpha-Minimum Eagle’s medium supplemented with 10% fetal bovine 
serum, 2 mM L-glutamine, 25μg/mL sodium ascorbate, and 100U/mL 
penicillin and 100μg/mL streptomycin) for 8 to 10 days with half the media 
being replaced at 4 days and every three days there after.  When cultures 
reached 80% confluence, cells were trypsinized, then plated onto 12-well 
tissue culture plates at a density of 1X105 cells per well.  To activate Notch 
signaling using immobilized Jagged-1, tissue culture plates were pre-coated 
with 10μg/mL of antibody against the Fc portion of human IgG (Jackson 
ImmonoResearch) for 1 hour then were incubated with the indicated 
concentration of recombinant rat Jagged-1/human Fc IgG chimeric protein 
(R&D Systems) for 2 hours.   For notch reporter activity experiments, 
Fc/Jagged-1 (Jag-1) or Fc/Trail (control) conditioned media (kind gifts from Dr. 
Tom Kadesch) was used to coat plates instead of the recombinant 




Induction of adipogenic differentiation:   First passage TSP2-null and wild type 
MSC were induced to undergo adipogenesis four days post plating using 
MDIT (57μM isobutyl-methylxanthine, 1μM dexamethasone, and 1μg/mL 
insulin, and 5μg/mL troglitazone) for three days then were maintained in 
1μg/mL insulin for the remainder of the differentiation experiments.  For γ-
secretase inhibitor (GSI) treatment, 1μM of L-685,458 (Sigma) was added 
daily to cells starting at the time of adipogenic induction.  Cells were fixed 10 
days post induction and extent of adipogenic differentiation was evaluated by 
staining with Oil Red-O.  
 
RNA extraction and quantitative RT- PCR:  RNA was extracted using RNeasy 
RNA extraction kit (QIAGEN) according to the manufacturer’s instruction and 
1μg of total RNA was reverse transcribed in 20μL reactions. 1μL of the cDNA 
generated was used for quantitative real-time PCR reactions using 
SybrGreen I for detection on ABI 7500 Fast real-time PCR machine.  Relative 
changes in gene expression were determined by the 2ΔΔC(T) method using β-
actin as an endogenous control. 
 
Generation of TSP2 type I repeat deletion constructions:  A retroviral 
construct missing all three type I repeat domains (aa 379-549, TSP2 delI3) 
was generated by first PCR amplifying a 1169 base pair fragment encoding 
amino acids 1- 378 (fragment 1) and a 1925 base pair fragment encoding 
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amino acids 550-1172 (fragment 2) and cloning into pCRII-TOPO vector 
(Invitrogen).  SfoI restriction sites that encoded a single glycine residue in-
frame were added to  the 3’ primer of fragment 1 and 5’ primer of fragment 2 
to allow ligation of the two fragments.  After sequence verification by direct 
sequencing, fragments 1 and 2 were released from pCRII-TOPO using 
BamHI and SfoI and SfoI and XbaI, respectively, then were ligated into Blue 
Script cloning vector digested with BamHI and XbaI.  The full-length TSP2 
(TSP2 FL) and TS2delI3 fragment was then released from BlueScripit using 
EcoRI and cloned into pRET retroviral vector digested with EcoRI.   
 
Retrovirus production and transduction:  Phoenix A (amphtropic) cells were 
plated at a density of 4x105 cells/well of a 6 well plate and cultured overnight.  
On the following day, the culture media was aspirated and exchanged with 
fresh media (DMEM, high glucose, 10% FBS, pen-strep, L-glutamine).  
Chloroquine dihydrochloride (Sigma, S764663) was added to phoenix cells 5 
minutes prior to transfection and 2μg of plasmid DNA was transfected into 
cells using the Promega Profection kit (E1200).  The media was changed 10 
hours after transfection and replaced with fresh medium.  Retroviral 
supernatant was collected on the following day and used to transduce 
GP+E86 cells.  GP+E86 cells were plated at 4x104 cells/well of a 6 well dish, 
and cultured overnight.  On the following day, retroviral supernatant from 
phoenix cells was .45 μm filtered, supplemented with protamine sulfate 
(5μg/mL) and 2mL was added to GP+E86 cells.  GP+E86 cells were 
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transduced again on the following day, and media replaced 24 hours later.  
Viral supernatant from GP+E86 cells was collected on the following two days 
and used to transduce C3H10T1/2 cells. 
 
Transient transfection and CSL-luciferase assay:  4X104 C3H10T1/2 cells 
were plated onto 12 well plates coated with either Fc-trail or Jag-1 and 36 
hours post plating, cells were co-transfected with 0.5μg of CSL-luciferase 
(synthetic DNA construct in which 4 tandem repeats of CSL binding elements 
drive expression of firefly luciferase, kind gift from Dr. Tom Kadesch) and 
100ng of pRL-TK (Promega, a constitutively active TK promoter driving 
expression of renilla luciferase activity) using Lipofectamine and Plus reagent 
(Invitrogen) according to the manufacturer’s instructions.  Cells were 
harvested 48 hours post transfection and firefly and renilla luciferase activities 
were measured using Dual Luciferase assay kit (Promega) according to the 
manufacturer’s instructions. 
 
Immunofluorescence staining of fracture callus:  Generation of tibial fractures 
in TSP2-null and wild type mice has been described (95).   Cleaved (activated) 
notch levels were assessed in serially sectioned (7 mm) paraffin embedded 
fractured tibias by immunofluorescence staining with a monoclonal antibody 
that recognizes notch receptors only after they have undergone γ-secretase 
cleavage (Cleaved Notch 1 (Val1744), Cell Signaling; 1:200).   After 
incubation with the primary antibody at 4ºC overnight, sections were treated 
 
 90 
with Alexafluor 594–labeled secondary antibody (1:200; Molecular Probes) at 
room temperature for 1 hour, mounted with Vectashield containing DAPI 
(Vector Laboratories) and visualized with fluorescence microscopy. 
 
Statistical Analysis:  Student’s t-tests were used to compare means between 




TSP2 decreases Jagged-1 mediated notch activation in mesenchymal 
lineage cells. 
 Previous studies have shown that TSP2 physically interacts with notch 
receptors and ligands and increases notch signal activation in lung cancer 
and smooth muscle cells (156).  To determine whether TSP2 can modulate 
notch signal activation in MSC, TSP2-null and wild type MSC were plated 
onto wells coated with either Fc-control or varying concentrations of Jagged-1  
and expression of notch target genes  Hey-1, Hey-2 and Hey-L, Hes-1 and 
Hes-5  were evaluated by quantitative RT-PCR (qPCR).  Hey-1, Hey-2 and 
Hey-L expression were induced in a dose dependent manner in both wild-
type and TSP2-null MSC (Figure 4.1) but Hes-1 and Hes-5 expression did not 
increase significantly by Jagged-1 treatment (data not shown).   Jagged-1 
induced increases in Hey-1, Hey-2 and Hey-L expression were significantly 
greater in TSP2-null MSC than wild type controls at all doses of Jagged-1 
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except for Hey-2 expression in cells plated on 0.625μg/mL of Jagged-1.  
Interestingly, the largest differences between TSP2-null and wild type MSC 
were observed in Hey-L expression (8.4, 10.7, 23.2, and 8.2 fold greater 
induction in TSP2-null over wild type control at 5, 2.5, 1.25 and 0.625μg/mL 
Jagged-1, respectively) and Hey-L was the notch target that showed the 
greatest responsiveness to Jagged-1 treatment (102 fold induction in Hey-L 
vs. 6.7 and 24.5 fold induction in Hey-1 and Hey-2, respectively, in wild type 
cells plated on 5μg/mL Jagged-1).  The smallest differences between TSP2-
null and wild type MSC were observed in Hey-1, the least Jagged-1 
responsive Hey family member, which showed 1.4, 1.5, 2.5 and 2.3 fold 
increase in expression in TSP2-null MSC over wild type controls treated with 
5, 2.5, 1.25 and 0.625μg/mL of Jagged-1, respectively.  Hey-2, which showed 
intermediate responsiveness to Jagged-1, also showed intermediate 
differences between TSP2-null and wild type MSC (2.8, 2.8, 4.9 and 3.1 fold 
increase in TSP2 null MSC over wild type controls treated with 5, 2.5, 1.25 
and 0.625μg/mL Jagged-1, respectively) (Figure 4.1).    
To determine whether TSP2 decreases notch activation, C3H10T1/2 
cells were stably transduced with retrovirus constructs carrying either GFP, a 
full length TSP2 (FL TSP2) construct or TSP2 lacking all three type I repeat 
domains (TSP2dl3).  Western-blot analysis of TSP2 proteins secreted into the 
media confirmed that TSP2dl3 is stable and is over-expressed at a similar 
level as FL TSP2 (Figure 4.2 A).  GFP, FL TSP2 or TSP2dl3 transduced cells 
were then plated on either Fc-control or 2.5μg/mL Jagged-1 coated plates 
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and Hey-1 mRNA expression was analyzed 4 days later (Figure 4.2 B).  
Induction of Hey-1 expression was significantly lower in FL TSP2 over-
expressing cells relative to GFP over-expressing controls (1.5 fold induction in 
FL TSP2 vs. 3.9 fold in GFP cells) but Hey-1 expression was induced at a 
similar level (3.5 fold) in TSP2dl3 over-expressing cells as GFP over-
expressing controls.  Hey-1 expression was evaluated in these experiments 
because Hey-1 showed the greatest responsiveness to Jagged-1 treatment in 
C3H10T1/2 cells when compared to Hey-2 and Hey-L (data not shown).  
These results indicate that TSP2 decreases notch target gene expression 
through its type I repeat domain.   
While Hes and Hey family members are well known targets of notch 
signaling, their expression can also be regulated by other transcriptional 
mechanisms that TSP2 could modulate.  To more directly measure whether 
TSP2 decreases canonical notch signaling, GFP or FL TSP2 over-expressing 
C3H10T1/2 cells were plated onto either Fc-trail or Jag-1 coated wells then 
were transiently transfected with a notch reporter (CSL-luciferase) construct.  
Similar to Hey-1 expression, notch reporter activity was significantly lower in 
TSP2 over-expressing cells when compared to GFP transduced controls (1.7 
fold in TSP2 over-expressing vs. 3.7 fold in GFP over-expressing cells) 
confirming that the decrease in Jagged-1 induced Hey-1 expression is 




γ-Secretase inhibition promotes adipogenesis in both wild-type and 
TSP2-null MSC.   
 We have shown in Chapter I that TSP2 decreases lipid accumulation in 
MSC.  Since notch activation is increased in the absence of TSP2 (Figure 4.1) 
we asked whether the increase in adipogenic differentiation in TSP2-null MSC 
was due to an increase in notch signaling.  To address this question, TSP2-
null and wild type MSC were induced to undergo adipogenesis in the 
presence or absence of a γ-secretase inhibitor (GSI) for 10 days and extent of 
lipid accumulation was measured by analyzing Oil Red-O incorporation 
(Figure 4.4).  Blocking notch signaling with GSI increased Oil Red-O staining 
1.9 and 1.5 fold over untreated controls in wild type and TSP2-null MSC, 
respectively.  There was no significant difference in GSI mediated increase in 
Oil Red-O staining between wild-type and TSP2-null MSC (Figure 4.4 B) 
suggesting that  either the effects of TSP2 on notch signal activation are 
upstream of γ-secretase or TSP2’s effect on adipogenic differentiation is not 
mediated through its effect on notch signal activation.   
 
Notch activation is increased in fracture calluses of TSP2-null mice. 
 Our results indicate that TSP2 decreases Jagged-1 mediated notch 
activation in vitro.  Previous studies have shown that TSP2 expression 
increases early during fracture healing and is highest at 5 days in a tibia 
fracture model when the healing fracture is composed of undifferentiated 
mesenchymal progenitors (95).  In order to evaluate whether TSP2 can 
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modulate notch signaling in vivo, we measured notch activation in day 5 
fracture calluses of wild type and TSP2-null tibia by immunofluorescence 
staining with antibody that specifically binds to notch receptors only after they 
have undergone γ-secretase cleavage (intracellular Notch – NICD).  An 
increase in cleaved notch was detected in TSP2-null fracture calluses relative 
to wild type controls (Figure 4.5).  These results suggest that TSP2 may 
inhibit notch signal activation in vivo.   
 
Discussion 
Previous studies have shown that TSP2 inhibits MSC proliferation and 
promotes osteogenic differentiation and in Chapter 2 we demonstrate that 
TSP2 inhibits adipogenesis.  The molecular mechanisms through which TSP2 
influences MSC are however unknown.  Here we provide one possible 
mechanism by demonstrating that TSP2 decreases notch signaling in MSC.   
 Our results contradict a previous report that showed TSP2 increases 
notch signaling in lung cancer cell lines and primary smooth muscle cells 
(156).  One possible explanation for this contradictory observation is that 
whether TSP2 promotes or inhibits notch activation could depend on the 
repertoire of notch ligands and receptors expressed by the signaling and 
receiving cells.  The cells used in the previous report were selected because 
they express high levels of Notch-3 but Notch-3 is expressed at relatively low 
levels in MSC.  In addition, receptor deletion experiments have demonstrated 
that simultaneous inactivation of Notch-1 and Notch-2 is mesenchymal 
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progenitors is sufficient to generate the same  skeletal phenotype as 
complete elimination of  γ-secretase activity, further supporting the notion that 
Notch-3 likely plays a minimal role in notch signaling in MSC (175).  Another 
possible explanation is the difference in the methodology of notch activation 
used in our study relative to that in the published report.  We used ligands 
immobilized to the tissue culture plates to activate notch signaling while the 
previous study used co-culturing with L-cells that express notch ligands.   It is 
therefore possible that whether TSP2 promotes or inhibits notch activation 
depends on the context in which the notch ligands are presented.   
 Our finding that blocking notch signaling using GSI increases 
adipogenic differentiation in both TSP2-null and wild type MSC suggests that 
TSP2’s effect on adipogenic differentiation may be independent of inhibiting 
notch signaling.  Alternatively, it is possible that TSP2 effect on notch 
signaling may be upstream of γ-secretase cleavage step.  This later 
explanation is supported by a previous report that showed GSI treatment 
completely abrogates notch activation regardless of the presence or absence 
of TSP2 (156).   The same study also showed that TSP2 effect on notch 
signaling requires Notch-3 ectodomain which further supports the notion that 
TSP2 acts upstream of γ-secretase to modulate notch signaling.    
Our results show increased cleaved Notch levels in TSP2-null fracture 
calluses suggest that TSP2 may inhibit Notch activation in vivo.   Previous 
reports have shown that fracture healing is altered in TSP2 null mice (95).  It 
is therefore possible that the increase in cleaved Notch levels is due to 
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differences in the cell types present in fracture callus of TSP2-null and wild 
type tibias and may not reflect a direct role for TSP2 in inhibiting notch 
activation in vivo.  Interestingly, notch signaling has been shown to regulate 
multiple components of the fracture healing process including MSC 
proliferation and chondrogenic and osteogenic differentiation as well as 
osteoclast maturation, and blood vessel formation (181-183).   It will be 
interesting to investigate whether the alteration in fracture healing in TSP2-
null mice is due to an increase in notch signal activation.   
TSP2 null MSC have an increase in MSC numbers at young age.  
Transgenic mice in which notch signaling is selectively inactivated in early 
mesenchymal progenitors have a decrease in MSC numbers at 8 weeks of 
age (175).  The results presented here indicate that TSP2 decreases Notch 
signaling therefore, it is possible that the increase in MSC number in young 
TSP2 null mice is due to an increase in notch signaling.  Similarly, TSP2-null 
MSC display a delay in osteogenic differentiation in vitro and our results 
(chapter III) show that Jagged-1 mediate notch activation decreases 
osteogenic differentiation.  The delay in mineralization in TSP2-null MSC 
could therefore also be due to an increase in notch activation in TSP2-null 
MSC relative to wild type controls.  We propose a model in which TSP2 acts 
to negatively modulate notch activation in MSC which in turn increases 
osteogenic differentiation and decreases MSC proliferation resulting in a 








































Figure 4.1 Jagged-1 mediated activation of Notch target gene 
expression is increased in TSP2-null MSC.  TSP2-null and wild type MSC 
were plated onto wells coated with either 0 (Fc-control), 5, 2.5, 1.25, or 0.625 
μg/mL Jagged-1.  mRNA was harvested 4 days later and expression of notch 
targets Hey-1, Hey-2 and Hey-L were measured by qPCR.   Graphs are mean 
+ S.D. of two independent experiments from two independent cell harvests 
each done in duplicate.  For each experiment, whole bone marrow from 3 wild 
type and 3 TSP2-null mice was pooled to yield MSC.  #=TSP2-null 





































































































Figure 4.2  TSP2 inhibits Jagged-1 induced Hey-1 expression through its 
Type I repeat domain.  C3H10T1/2 cells were stably transduced with 
retrovirus carrying GFP, full length TSP2 (FL TSP2) or TSP2 in which all 
three type I repeat domains have been deleted (TSP2dl3).  Media was 
collected and stable expression of TSP2dl3 was confirmed by western-
blotting with a TSP2 monoclonal antibody.  (A).  Cells were plated onto wells 
coated with either Fc control (Fc) or 2.5μg/mL Jagged-1 and  were harvested 
4 days later and Hey-1 mRNA expression was measured using qPCR (B).   
Graphs represent Mean + S.D of two independent experiments each done in 
duplicate.  #= FL TSP2 transduced cells significantly different from GFP 
























































Figure 4.3 TSP2 over-expression decreases Jagged-1 induced notch 
reporter activity.  GFP or full-length TSP2 over-expressing C3H10T1/2 cells 
were plated on Fc-trail (control protein), or Fc-Jagged-1 (Jag-1) coated wells 
then were co-transfected with notch reporter (CSL-Luciferase) and pRL-TK 
constructs as described in the materials and methods section.   CSL-
luciferase activity was measured 48 hours later and was normalized to pRL-
TK activity to control for differences in transduction efficiency.  Fold changes 
in normalized notch reporter activity in cells plated on Jag-1 relative to cells 
plated on Fc-trail are depicted in the graphs.  Data shown are mean + S.D. of 
two independent experiments each done in duplicate.  #=TSP2 over-






































































Figure 4.4 γ-secretase inhibitor treatment promotes adipogenesis in 
both wild-type and TSP2-null MSC.  TSP2-null and wild type MSC were 
induced to undergo adipogenic differentiation in the presence or absence of 
L-685,458 (GSI) for 10 days then were stained with Oil Red-O. (A) plates 
were scanned and a representative set is shown. (B) Oil Red-O was 
extracted and quantified by measuring absorbance at 540nm. The relative 
increase in Oil Red-O absorbance in GSI treated cells (+GSI) over un-treated 
controls (No GSI) from two independent experiments each done in duplicate 
was averaged and is depicted in the graphs.  Error bars + S.D.  
#=Significantly different from No GSI controls. p< .05.  The fold change in Oil 
Red-O absorbance between GSI treated TSP2-null and wild type MSC was 















































































Figure 4.5 Cleaved Notch (activated notch) levels are increased in 
fracture calluses of TSP2 null mice.   7 micron sections of Day 5 fracture 
calluses from TSP2-null and wild-type control mice were stained with primary 
antibody that only recognized notch receptors after they have been cleaved 
with γ-secretase (Anti-Cleaved Notch).  Staining with isotype control antibody 
served as control for specificity of cleaved notch antibody.  Nuclei are stained 
blue (DAPI), and cleaved notch is located intracellularly and is stained red. 
Pictures shown are representative of fractured tibias from three wild type and 
three TSP2-null mice.







CONCLUSIONS AND FUTURE DIRECTIONS 
 
Like other stem cells, we presume that mesenchymal stem cells reside 
within a niche where they receive multiple signals from local and systemic factors.  
These signals are then processed, integrated and ultimately cell fate is 
determined.  ECM, in addition to serving as a substrate for cell adhesion, plays a 
role in how cells receive and respond to these signals.  Previous reports have 
shown that TSP2 produced by MSC, inhibits their proliferation and promotes their 
osteogenic differentiation (1, 2).  In this dissertation, we examined the role of 
TSP2 on influencing adipogenic differentiation and found that TSP2-null MSC 
accumulate more lipid than wild type MSC.   TSP2-null female mice are also 
heavier than wild type mice because of an increase in adipose tissue.  Stromal 
vascular cells isolated from TSP2-null mice show both increased proliferation and 
adipogenic differentiation.   
 Although it is clear that TSP2 plays an important modulatory role in MSC 
function, the molecular mechanisms through which it exerts an effect on MSC are 
unknown.  Previous reports have shown that TSP2 can physically interact and 
promote Notch signal activation in other cell types (3).  We examined the effect of 
activating notch signaling in vitro using immobilized Jagged-1 and found that it 
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increases MSC proliferation and inhibits osteogenic differentiation.  Jagged-1 
also increases lipid accumulation when cells were induced to undergo 
adipogenesis primarily by increasing cell number.   The effects of activating notch 
signaling in vitro therefore are similar to the effects of an absence of TSP2; in 
both instances, there is a decrease in osteogenic differentiation and an increase 
in lipid accumulation and proliferation.    
We examined whether TSP2 can modulate notch signaling in MSC and 
found that Jagged-1 mediated notch target gene expression was enhanced in 
TSP2-null MSC, and that over-expressing TSP2 in an MSC line decreased notch 
target gene expression and notch reporter activity.  We propose a model 
whereby TSP2 negatively regulates notch signaling which in turn decreases MSC 
proliferation and increases osteogenic differentiation.  In the absence of TSP2, 
notch signaling increases and results in a decrease in osteogenic differentiation 
and an expansion of the osteoprogenitor pool (Figure 5.1). 
 Our results which show TSP2 decreases notch activation are in contrast to 
Meng et al’s study that showed TSP2 increases notch activation in lung cancer 
cell lines and in primary smooth muscle cells (3).  One possible explanation for 
these contradictory results is that the effects of TSP2 on promoting or inhibiting 
notch signaling are dependent on the repertoire of notch receptors and ligands 
expressed by affected cells.  A recent study by Benedito et al showed that 
expression of notch targets Hes-1 and Hey-1 was increased when Jagged-1 was 
inactivated in endothelial cells.  Using various in vitro experiments, the authors 
demonstrated that Jagged-1 antagonizes delta-like-4 mediated notch activation 
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and its ability to do so was dependent on whether the glucosaminyltransferase 
manic-fringe was over-expressed in either the signaling or receiving cell (4).   
TSP2 has been shown to interact with Jagged-1 but whether it also interacts with 
delta-like-4 is unknown.  It is possible that TSP2 interferes with the ability of 
Jagged-1 to block delta-like-4 mediated notch activation and causes an increase 
notch signaling when both ligands are expressed but decreases notch signaling 
when only Jagged-1 is expressed.  Future studies should address whether 
differences in ligand and/or receptor expression account for the different effects 
TSP2 has on MSC versus the cell types used in the previous report.  By 
extension, the effects of different notch ligands on notch activation and MSC 
proliferation and differentiation should also be investigated.    
Whether the effects of TSP2 on MSC proliferation and/or differentiation 
are mediated through notch signaling will require demonstration of direct 
functional interactions. This will require better characterization of the molecular 
interaction between TSP2 and notch.  Our experiments that show GSI treatment 
increases adipogenesis in both TSP2-null and wild-type cells suggests that TSP2 
exerts its effect on notch activation upstream of the γ-secretase cleavage step, 
perhaps by interfering with notch ectodomain shedding.  Examining the effects of 
TSP2 on notch signaling when different notch receptor constructs (full-length, 
lacking ectodomain, and NICD) are over-expressed should allow elucidation of 
notch domains responsible for interaction with TSP2.  We show here that the 
type I repeat domains are required for TSP2s’ effect on inhibiting notch signaling.  
Determining if the type I repeats are required for TSP2 effects on MSC function 
 
 105 
should also provide some evidence for whether TSP2 acts through notch to exert 
its influence on MSC. 
We also examined the effects of expressing a dominant negative form of 
mastermind like-1(dnMAML) in bone development in vivo.  We found that 
Col2.3Cre driven expression of dnMAML causes vertebral malformations similar 
to that seen in Alagille Syndrome patients.   Alagille Syndrome is caused by 
mutations in Jagged-1 and the vertebral malformations in this disease are 
thought to arise from disruption of cyclic expression of notch target genes during 
somitogenesis.  In addition to vertebral malformations, Alagille Syndrome 
patients develop osteoporosis at a young age.  Whether the decrease in bone 
mass seen in these patients is due to mutations in Jagged-1 having an effect on 
skeletal tissue or whether it arises secondary to other features of the syndrome is 
however not well understood.  The observation that Col2.3Cre/dnMAMLfl/- mice 
develop similar vertebral malformations to Alagille syndrome patients suggests 
that the Col2.3 promoter drives dnMAML expression in somites.  
Col2.3Cre/dnMAMLfl/-  mice may therefore be a useful model to elucidate the 
mechanism for vertebral malformation and decrease in bone mass seen in 
Alagille Syndrome patients.   
 We also show that driving dnMAML expression in early limb-bud 
mesenchymal progenitors using Prx-1Cre mice results in a decrease in 
trabecular bone volume fraction at 8 weeks of age without causing any significant 
change in any trabecular bone parameter at 6 or 14.5 months of age.  Our results 
are in contrast to previous reports by Hilton et al that showed massive 
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accumulation of trabecular bone at 8 weeks and a severe decrease in bone mass 
at 6 months of age when notch signaling was inactivated using the same Prx-
1Cre mice to delete Notch 1 and Notch 2 (5).  One possible explanation for the 
contradictory observations is that the effects of reducing notch activation using a 
dominant negative approach results in a different phenotypic outcome than 
inactivating the pathway using deletion models such those used in the Hilton et al 
study.  Another possible explanation is that inactivating only CSL mediated, 
canonical notch signaling using dnMAML gives a different outcome than 
disrupting Notch signaling upstream of CSL.  Hilton et al’s study has shown that 
Hey-1 concentration is the limiting factor in the interaction between Hey-1 and 
Runx-2 therefore it possible that reducing Hey-1 levels may not be sufficient to 
relieve its effect on inhibiting Runx-2’s activity.  To determine that the effects of 
blocking canonical notch signaling specifically results in a different outcome than 
interfering with notch signaling upstream of CSL (non-canonical signaling) will 
therefore require  testing in other mouse models, such as floxed RPBJ-κ mice 
(gene coding for CSL protein) in which the CSL gene can be conditionally 
disrupted in mice using Cre recombinase.   
We found that inducing dnMAML expression globally starting at 8 weeks in 
Mx1Cre/dnMAMLfl/fl mice results in a decrease in trabecular bone mass at 6 
month of age.   The observation that 6 month old  Prx-1Cre/dnMAML mice do not 
display any change in trabecular bone, in conjunction with the observation that 
CFU-F numbers are not significantly altered in Mx1Cre/dnMAML mice, suggests 
that the decrease in bone mass in Mx1Cre/dnMAML mice may be due to an 
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increase in bone resorption rather than due to a change in bone formation. 
Histomorphometric analysis of Mx1Cre/dnMAML bones should be preformed to 
determine whether the decrease in bone mass arises from a decrease in bone 
formation or an increase in bone resorption.  The decrease in bone mass when 
dnMAML is globally activated should raise caution to treatment strategies that 
aim to pharmacologically block notch signaling to increase bone formation.   As 
well, γ-secretase inhibitors are in clinical trials for treatment of Alzheimer’s 
Disease. Our results suggest that a decrease in bone mass may arise as a side-
effect from such treatments.    Our observation that immobilized Jagged-1 
increases MSC numbers and that the cells retain the potential to differentiate into 
adipocytes as demonstrated by an increase in lipid accumulation indicates that 
transiently activating notch signaling using immobilized ligands may be useful to 
expand MSC in vitro and in vivo.   
An intriguing question that has emerged from our work (and which has 
been conceptually explored in other studies) is whether notch signaling maintains 
“stemness” in MSC.  “Stemness” can be defined as the ability to undergo self 
renewal, but cell surface markers that identify murine MSC with self-renewal 
potential are not currently available.  An alternative approach to assess self-
renewal is to perform in vitro assays in which individual CFU-F’s are passaged 
and re-plated at low density then determining the number of secondary colonies 
that are derived from the initial colony.  Such experiments are difficult because 
mouse MSC require non-adherent cells and the non-adherent cells often contain 
cells that are also able to form colonies when they are re-plated.  A study by 
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Sacchetti et al recently showed that a self-renewing population of 
osteoprogenitor cells in humans can be prospectively isolated using the cell 
surface marker CD146.  CD146 expression was also shown to decreases with 
osteogenic differentiation and with passage (6).  Whether activating notch 
signaling maintains “stemness” should be investigated in human cells by plating 
MSC on Jagged-1 coated plates and determining whether the number of cells 
that express CD146 increases.  
Elucidation of the molecular mechanism by which notch may maintain 
“stemness” should also be pursued further.  Previous studies have shown that 
both Hey-1 and NICD physically interact with Runx-2 and inhibits its 
transcriptional activity at the osteocalcin promoter.  In addition to its role in 
activating transcription of genes required for osteogenesis, intriguing studies by 
Dr. Gary Stein’s group have shown that Runx-2 remains associated with 
chromosomes during mitosis and causes epigenetic changes in daughter cells 
that program them to maintain a differentiated phenotype (7).  It will be 
interesting to determine whether notch signaling interferes with this function of 
Runx-2 to maintain MSC “stemness” by activating the notch signaling pathway 
and determining whether Runx-2 is associated with mitotic chromosomes.  It will 
also be interesting if activating notch signaling in osteoblasts could cause de-
differentiation.  As an example, fate tracking experiments in which permanently 
labeled osteoblasts (such as by osteocalcin-cre mediated recombination and 
expression of a floxed GFP protein) are plated on Jagged-1 then induced to 
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differentiate into other lineages can be performed to assess whether notch 

















Figure 5.1  Model for TSP2-Notch interaction in MSC fate determination.  In 
this model TSP2 negatively regulates notch signaling which in turn decreases 
MSC proliferation and increases osteogenic differentiation.  In the absence of 
TSP2, notch signaling increases and results in a decrease in osteogenic 
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